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Importance: Thromboses after the COVID-19 vaccine ChAdOx1-S have been 
reported. Better understanding of population-level thrombotic risks after COVID-19 
vaccination is needed. 
Objective: Quantify associations of vaccination with ChAdOx1-S and BNT162b2 with 
major arterial, venous and thrombocytopenic events. 
Design: Cohort study based on linked electronic health records, with follow up from 
December 8th, 2020, to March 18th, 2021. 
Setting and participants: Adults registered with an NHS general practice in England 
and alive on December 8th, 2020. 
Exposures: First dose of vaccination with ChAdOx1-S and BNT162b2. 
Main Outcomes and Measures: Incidence rates and hazard ratios (HRs) for major 
arterial, venous and thrombocytopenic outcomes 1-28 and >28 days after first 
vaccination with ChAdOx1-S or BNT162b2 vaccine. Analyses were performed 
separately for ages <70 and ≥70 years, and adjusted for age, sex, comorbidities, and 
social and demographic factors. 
Results: Of 46,162,942 adults, 21,193,814 (46%) had their first vaccination during 
follow-up. Adjusted HRs 1-28 days after ChAdOx1-S, compared with pre-vaccination 
rates, at ages <70 and 70 respectively, were 0.97 (95% CI: 0.90-1.05) and 0.58 
(0.53–0.63) for venous thromboses, and 0.90 (0.86-0.95) and 0.76 (0.73-0.79) for 
arterial thromboses. Corresponding HRs for BNT162b2 were 0.81 (0.74–0.88) and 
0.57 (0.53–0.62) for venous thromboses, and 0.94 (0.90-0.99) and 0.72 (0.70-0.75) 
for arterial thromboses. HRs for thrombotic events were higher at younger ages for 
venous thromboses after ChAdOx1-S, and for arterial thromboses after both vaccines. 
Rates of intracranial venous thrombosis (ICVT) and thrombocytopenia in adults aged 
<70 years were higher 1-28 days after ChAdOx1-S (adjusted HRs 2.27, 95% CI:1.33–
3.88 and 1.71, 1.35–2.16 respectively), but not after BNT162b2 (0.59, 0.24–1.45 and 
1.00, 0.75–1.34) compared with pre-vaccination. The corresponding absolute excess 
risks of ICVT 1-28 days after ChAdOx1-S were 0.9–3 per million, varying by age and 
sex.  
Conclusions and Relevance: 
Increases in ICVT and thrombocytopenia after ChAdOx1-S vaccination in adults aged 
<70 years are small compared with its effect in reducing COVID-19 morbidity and 
mortality, although more precise estimates for adults <40 years are needed. For 
people aged ≥70 years, rates of arterial or venous thrombotic, events were generally 
lower after either vaccine. 
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In late February 2021 several groups reported a rare syndrome of thrombosis and 
thrombocytopenia after vaccination against severe acute respiratory syndrome 
coronavirus-2 disease 2019 (COVID-19) with ChAdOx1-S (developed by Oxford-
AstraZeneca).1–3 Thromboses were found in unusual sites such as the cerebral venous 
sinuses, or mesenteric or portal veins. This syndrome, named ‘vaccine-induced 
immune thrombotic thrombocytopenia’ (VITT), is probably due to an autoimmune 
response to platelet factor 4 (PF4) in the absence of exposure to heparin.1 Whether 
the risk of common thrombotic illnesses is also increased post-vaccination is 
uncertain, although there have been reports of post-vaccination ischaemic stroke and 
intracerebral haemorrhage.1,3,4 
Estimates of vaccine-associated excess risk based on case reports and routine 
reporting may be biased if diagnostic thresholds vary between vaccinated and 
unvaccinated individuals or there is less than population-wide coverage. In England, 
the National Health Service (NHS) provides almost all healthcare; therefore, linked 
health care records provide comprehensive, population-wide data on outcomes before 
and after vaccination.5 Vaccination in England began on December 8th 2020: the first 
groups vaccinated were care home residents, then those aged ≥80 years and frontline 
health and social care workers. Those clinically extremely vulnerable were invited 
alongside people aged ≥70 years, and those with other co-morbidities aged <65 
alongside people aged >65 years. Consequently, vaccinated individuals are expected 
to have higher rates of venous and arterial events. 
We conducted a cohort study using routinely collected, linked health data from multiple 
sources, covering almost the entire English adult population (>46 million). 
Associations of ChAdOx1-S and BNT162b2 (developed by Pfizer–BioNTech) with 
major venous and arterial events and thrombocytopenic haematological outcomes 
were estimated from the start of the vaccination program to mid-March 2021, before 
VITT surveillance was widespread.  
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The study population was adults (aged ≥18 years), alive and registered with an English 
NHS general practice on December 8th 2020. The data resource5 includes primary 
care data (GPES data for Pandemic Planning and Research, GDPPR) from 98% of 
general practices linked at individual-level to nationwide secondary care data including 
all NHS hospital admissions (Hospital Episode Statistics (HES) and Secondary Uses 
Service (SUS) data from 1997 onwards), COVID-19 laboratory testing data, COVID-
19 vaccination data (NHS England immunisation management system), national 
community drug dispensing data (NHS BSA Dispensed Medicines from 2018) and 
death registrations. We accessed and analysed pseudonymised data within NHS 
Digital’s secure, privacy protecting Trusted Research Environment.6 
Covariates 
Covariates were defined from primary care, hospital admissions, community drug 
dispensing and COVID-19 laboratory testing data, using phenotyping algorithms 
verified by specialist physicians (see supplementary data). Phenotypes for co-
morbidities, risk factors and other covariates used Systematized Nomenclature of 
Medicine Clinical Terms (SNOMED-CT) concepts for primary care data, and ICD-10 
codes for hospital admission data. Sex, age, region, deprivation and smoking status 
were defined as the latest recorded in primary care records before 8th December 2020, 
and the most recently recorded ethnicity in either primary care or hospital admissions 
records was used. History of diabetes, depression, obesity, cancer, chronic 
obstructive pulmonary disease, chronic kidney disease, stroke, MI, DVT or PE, cancer, 
thrombophilia, liver disease or dementia were defined as any record in primary care 
and/or hospital admission data before December 8th 2020. The number of unique 
diseases in SNOMED-CT for the year before December 8th 2020 were derived from 
primary care records and major surgery in the previous year from hospital admission 
records (using the Office of Population Censuses and Surveys classification of 
surgical procedures). 
A history of coronavirus (SARS-CoV2) infection was defined as either a positive 
COVID-19 antigen test in national laboratory data covering swab tests performed in 
the general population and hospitals or a confirmed COVID-19 diagnosis in primary 
care or hospital admission records. Prior medication was defined using community 
dispensing data on all prescriptions dispensed by community pharmacists, appliance 
contractors, and doctors in England. British National Formulary (BNF) codes were 
used to define the total number of types of medication prescribed and dispensed in 
the following groups: antiplatelets, antihypertensives, lipid lowering agents, oral 
anticoagulants, combined oral contraceptives, and hormone replacement therapy. 
Outcomes 
Outcomes were derived from primary care data, hospital admission data (SUS 
dataset) and the national death registry (see supplementary material).7 Specialist 
clinician-verified SNOMED-CT and ICD-10 rule-based phenotyping algorithms were 
used to define fatal or non-fatal (i) arterial thrombotic events: myocardial infarction 
(MI), ischaemic stroke (ischaemic or unclassified stroke, spinal stroke or retinal 
infarction), other non-stroke non-MI arterial thrombo-embolism; (ii) venous thrombo-
embolic events: pulmonary embolism (PE), lower limb deep venous thrombosis (DVT), 
intracranial venous thrombosis (ICVT), portal vein thrombosis, and venous thrombosis 
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at other sites; (iii) thrombocytopenic haematological events: any thrombocytopenia 
(idiopathic, primary, secondary or unspecified), disseminated intravascular 
coagulation (DIC), and thrombotic thrombocytopenic purpura (TTP); (iv) death from 
any cause; (v) other vascular outcomes: haemorrhagic stroke (intracerebral or 
subarachnoid), and mesenteric thrombus for which available codes did not distinguish 
between arterial or venous causes; and (v) lower limb fracture as a control condition 
unlikely to be affected by vaccination. The event date was the earliest of: start of 
hospital episode, death, or recorded date of primary care event or consultation. Events 
within the death registry were identified based on underlying cause of death and in 
hospital admission data based on the primary cause of the care episode. 
Statistical analyses 
Data were analysed according to a pre-specified plan, published on GitHub on April 
27th 2021.8 Follow-up was from December 8th 2020 to March 18th 2021, the date the 
European Medicine Agency (EMA) Pharmacovigilance Risk Assessment Committee 
(PRAC) discussed the first reported complications of vaccination, after which 
diagnostic effort is expected to be concentrated in people receiving ChAdOx1-S.9 Any 
cell numbers <5 and any potentially disclosive numbers <10 are not reported exactly 
but as <5 and <10 respectively. 
Follow up time for each person was split into periods before, and 1-28 and >28 days 
after, first vaccination. Censoring was at the earliest of the outcome, death, March 18th 
2021 and, in analyses of specific vaccines, receipt of the other vaccine. Incidence 
rates per 100,000 people per year were estimated for each outcome, before and 1-28 
and >28 days after vaccination. 
Cox models with time zero December 8th 2020 were fitted, ensuring that all analyses 
accounted for changes in rates of outcome events with calendar time. Hazard ratios 
comparing the periods 1-28 and >28 days after vaccination with unvaccinated or pre-
vaccination person-time (reference) were estimated. Cox models were fitted 
separately by age group (<70 and ≥70 years), both overall and separately for males 
and females. All Cox models were stratified by geographic region. For rare outcomes, 
sex-specific hazard ratios were estimated from vaccine-sex interaction terms. For 
computational efficiency, each model included data from all people with, and a 10% 
random sample of people without, the outcome of interest; analyses incorporated 
inverse probability weights to account for this sampling. Confidence intervals were 
derived using robust standard errors. 
Region-; age-sex-region-; and fully-adjusted hazard ratios (HR) for associations of 
ChAdOx1-S and BNT162b2 with outcome events were estimated. The following 
covariates were included in all fully-adjusted models: (a) sex, age and age2, ethnicity, 
postcode-derived deprivation level; (b) risk factors for venous thromboses 
(anticoagulant medication, combined oral contraceptive medication, hormone 
replacement therapy medication, history of PE or DVT, and history of coronavirus 
infection); (c) risk factors for arterial thromboses (diabetes, hypertension, smoking, 
antiplatelet medication, blood pressure lowering medication, lipid lowering medication, 
anticoagulant medication, history of stroke, and history of MI); (d) further covariates 
selected using a backwards stepwise procedure with p value threshold 0.2, from 
models using MI as outcome (separately in the four groups defined by age and sex). 
The covariates had few missing values (apart from ethnicity, for which the 5.9% 
‘missing’ were included as a separate category); hence all analyses used “complete-
cases”. 
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Sensitivity analyses examined outcome events recorded as the primary or secondary 
reason for admission or death in hospital admissions or death records; fatal outcome 
events (those followed by death from any cause within 28-days); and all venous and 
all arterial thrombotic outcome events associated with thrombocytopenia. Effect 
modification by age, sex, ethnicity, medication, diabetes, deprivation and medical 
history was examined for all venous and all arterial thromboses. 
Absolute excess risks of ICVT were estimated by applying estimated hazard ratios to 
incidence rates of first fatal or non-fatal events in decades of age and sex in 2019, 
derived from linked hospital and death records. 
The study was approved by the Newcastle & North Tyneside 2 Research Ethics 
Committee (20/NE/0161), the NHS Digital Data Access Request Service (DARS-NIC-
381078-Y9C5K) and the British Heart Foundation Data Science Centre CVD-COVID-
UK Approvals and Oversight Board.  
Data manipulation and analyses used SQL and Python in Databricks and RStudio 
(Professional) Version 1.3.1093.1 driven by R Version 4.0.3. All code and phenotypes 
are available at github.com/BHFDSC/CCU002_02.  
 
RESULTS 
On December 8th 2020, 46,162,942 eligible adults were registered with an English 
general practice. By March 18th 2021, 21,193,814 (46%) had received their first 
vaccination (8,712,477 BNT162b2; 12,481,337 ChAdOx1-S) (supplementary figure 1). 
Post-vaccination person years of follow up for ages <40, 40-69 and ≥70 years 
respectively were, for ChAdOx1-S: 91,206, 417,160 and 401,343 person years; for 
BNT162b2: 159,856, 427,874, and 583, 890 person years. 
The risks per 100,000 from December 8th 2020 to March 18th 2021 were: any venous 
thrombosis 45.3, any arterial thrombosis 189; thrombocytopenia 4.2 (Table 1). Risks 
of venous and arterial thromboses were higher in people with co-morbidities and with 
increasing age and deprivation, and varied substantially by ethnicity. Absolute and 
relative increases in risk with increasing age and deprivation were greater for arterial 
than for venous thromboses. The risk of venous thromboses was higher in people with 
prior DVT or PE, thrombophilia, or oral anticoagulant medication, while the risk of 
arterial thromboses was higher in people with prior stroke, MI or antiplatelet 
medication. The risk of thrombocytopenia increased with age and co-morbidities but 
varied less markedly with ethnicity and deprivation than the risk of venous or arterial 
thromboses. 
Incidence rates of all events varied substantially pre- and post-vaccination (Table 2). 
Before vaccination, the incidence rates per 100,000 per year were: all venous 
thromboses 141 (mostly PE and DVT), ICVT 1.97; portal vein thrombosis 1.15; any 
arterial thrombosis 549 (with slightly more ischaemic stroke (273) than MI (268)); any 
thrombocytopenia 13, with very low rates of DIC (0.12) and TTP (0.67). For each 
vaccine, crude incidence rates of venous and arterial thromboses, haemorrhagic 
stroke, mesenteric thrombus and thrombocytopenia were higher after than before 
vaccination in the under 70s, but lower after than before vaccination in the over 70s. 
The additional confounding factors selected using backward selection were: for both 
sexes and age strata, previous diagnosis of cancer, number of unique diseases in the 
last year, surgery in the last year, obesity, liver disease; additionally for women aged 
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<70, history of depression and total number of types of medication (by BNF chapters); 
additionally for men aged <70, history of SARS-CoV2 infection and thrombocytopenia; 
and additionally for men and women aged 70, chronic kidney disease and dementia.  
Crude hazard ratios were substantially attenuated after adjusting for age, and further 
attenuated after adjusting for confounding factors. For example, in <70 year-olds the 
HRs 1-28 days post- versus pre-vaccination were attenuated from 2.81 to 2.27 for 
ICVT; from 4.85 to 1.71 for thrombocytopenia; and from 3.21 to 0.90 for ischaemic 
stroke (supplementary table 1). 
In people aged <70 years, the fully adjusted HR for any venous thrombosis was 0.97 
(95% CI:0.90-1.05) 1–28 days after ChAdOx1-S compared with before vaccination, 
with similar adjusted HRs for PE and DVT. Compared with before vaccination, the 
hazard of any venous thrombosis was lower 1-28 days after ChAdOx1-S in people 
aged ≥70 (adjusted HR 0.58, 95%CI:0.53–0.63) and 1–28 days after BNT162b2 (<70: 
HR 0.81, 0.74–0.88; 70 HR: 0.57, 0.53–0.62), with similar adjusted HRs for PE and 
DVT. (Figure 1, supplementary table 1). 
In people aged <70 years, adjusted HRs for ICVT were 2.27 (95%CI: 1.32–3.88) 1-28 
days after ChAdOx1-S and 0.59 (0.24–1.45) 1-28 days after BNT162b2. HRs were 
similar in men and women. In a post-hoc analyses, in people aged <40 years, the HRs 
1-28 days after vaccination were 3.73 (1.58–8.83) and 1.07 (0.33–3.48) for ChAdOx1-
S and BNT162b2 respectively. The same estimates for people 40-69 years were 1.93 
(1.19–2.13) and 0.74 (0.29–1.87). In people aged ≥70 years, associations of 
vaccination with ICVT were estimated imprecisely (<10 events for ChAdOx1-S and 8 
for BNT162b2 (Figure 1, supplementary table 1).  
Adjusted HRs for any arterial thrombosis 1-28 days after ChAdOx1-S were 0.90 
(95%CI: 0.86-0.95) and 0.76 (0.73–0.79) in people aged <70 and 70 years 
respectively. Corresponding HRs 1-28 days after BNT162b2 were 0.94 (0.90-0.99) 
and 0.72 (0.70–0.75). HRs were similar for MI and ischaemic stroke, and >28 days 
after vaccination (Figure 2, supplementary table 1). 
In people aged <70 years, adjusted HRs for thrombocytopenia were 1.71 
(95%CI:1.35–2.16) 1–28 days and 1.69 (1.16–2.46) >28 days after ChAdOx1-S. 
Corresponding HRs after BNT162b2 were 1.00 (0.75–1.34) and 0.97 (0.66–1.41). For 
those aged ≥70 years, adjusted HRs for thrombocytopenia 1-28 days after vaccination 
were similar for ChAdOx1 (0.79, 95%CI: 0.56–1.10) and BNT162b2 (0.68, 0.51-0.90) 
(Figure 3, supplementary table 1). 
Adjusted HRs for lower limb fracture 1–28 days after ChAdOx1-S were 0.85 (95% CI: 
0.77–0.93), and 0.83 (0.78–0.89) in people aged <70 and 70 years respectively. 
Corresponding HRs after BNT162b2 were 0.93 (0.84–1.02) and 0.69 (0.66–0.73). 
(Figure 3, supplementary table 1). Adjusted HRs for all-cause mortality 1–28 days after 
ChAdOx1-S were 0.37 (95%CI: 0.35–0.39), and 0.28 (0.28–0.29) in people aged <70 
and 70 years respectively. Corresponding HRs after BNT162b2 were 0.24 (0.22–
0.26) and 0.19 (0.19–0.20) (supplementary figure 2, supplementary table 1).  
Subgroup analyses 
HRs for all venous and for all arterial thrombotic events 1-28 days after vaccination 
were lower in older age groups for each vaccine (all interaction p values <0.0001) 
(supplementary table 2). HRs for venous thromboses were >1 1-28 days after 
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compared with before vaccination in people aged <50 years for ChAdOx1-S but not 
BNT162b2. HRs for arterial thromboses were >1 1-28 days after compared with before 
vaccination in people aged <50 years for both ChAdOx1-S and BNT162b2. A higher 
proportion of venous thromboses in those aged <40 years compared with those aged 
≥40 years were due to ICVT. A higher proportion of arterial thromboses at age <40 
was due to stroke than at ages 40–59 and 60–69 years. Less marked trends for lower 
HRs in older individuals were observed for HRs >28 days after vaccination. Despite 
modest differences between the magnitude of HRs in subgroups defined by sex, 
ethnicity, prior COVID, COCP, diabetes, deprivation or history of MI, DVT or PE, 
anticoagulation or antiplatelet medication, HRs in all of these subgroups were 
consistent with lower rates of arterial or venous thromboses after vaccination with 
ChAdOx1-S or BNT162b2. 
Sensitivity analyses 
When using a less restrictive outcome definition (outcomes recorded as primary or 
secondary reason for admission), estimated HRs were consistent with those from 
analyses of outcomes in the primary position (supplementary figure 3). Similarly, 
estimated HRs for fatal outcomes, were similar to HRs for outcomes in the primary 
position (supplementary figure 4). There were very few people for whom outcomes in 
the primary position were recorded as well as thrombocytopenia in any position in the 
same hospital admission or death record (after ChAdOx1-S and BNT162b 
respectively: ICVT 7 and 0; all arterial thromboses 47 and 58; all venous thromboses 
37 and 26).  
Intracranial venous thrombosis 
Characteristics were similar among patients who developed ICVT while unvaccinated, 
after ChAdOx1 and after BNT162b. Most were women (66% unvaccinated, 67% 
ChAdOx1, 79% BNT162b), of white ethnicity (75% unvaccinated, 92% ChAdOx1, 
100% BNT162b), and had no prior co-morbidities (71% unvaccinated, 50% ChAdOx1, 
50% BNT162b). Patients with post vaccination ICVT were older than those with pre-
vaccination ICVT. Post-vaccination, no patients had a recorded history of 
thrombophilia, and fewer than 5% had a recorded dispensed prescription of oral 
contraceptive or HRT (supplementary Table 3). 
Applying the HR for ICVT 1-28 days after ChAdOx1 to the monthly incidence of ICVT 
in 2019, the excess risk of ICVT in the month after vaccination with ChAdOx1 among 
those aged 19–30, 31–39, 40–49, 50–59 and 60–69-years was estimated to be, 
respectively: 0.9, 1.1, 1.5, 1.5 and 1.6 per million in men and 3.0, 2.7, 2.0, 1.6 and 1.5 
per million in women. 
DISCUSSION 
In this cohort study, which included almost all adults alive in England at the start of the 
national COVID-19 vaccination programme, vaccination with ChAdOx1-S, but not 
BNT162b2, was associated with approximately 2-fold higher rates of ICVT and 
hospitalisations due to thrombocytopenia in people aged under 70 years, after 
adjusting for a comprehensive range of demographic characteristics and 
comorbidities. The corresponding absolute increases in the risk of these events were 
very small. ChAdOx1-S and BNT162b2 were associated with lower hazards of major 
vascular events after vaccination in those aged ≥70 years. Analyses stratified by age 
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suggest that in people aged <50 years, rates of venous thromboses were higher 1-28 
days after vaccination with ChAdOx1-S, and that rates of arterial thrombotic events 
were higher 1-28 days after vaccination with ChAdOx1-S or BNT162b2, compared 
with rates in unvaccinated people. 
The large population analysed (including almost 10 times as many vaccinated people 
as any other published study) adds substantial precision to estimated associations of 
thromboses with vaccination, which is of particular importance for very rare events and 
associations in subgroups. The extensive data linkages across different healthcare 
settings enabled adjustment for a wide range of confounding variables. The analysed 
population is slightly larger than the mid-year estimate of the 2020 English population 
aged ≥18 (44,456,850) that excluded short-term residents and students, and modelled 
international migrant numbers.10 
Smaller Danish and Norwegian electronic health record studies reported a small 
excess of intracranial haemorrhage (2 per 100,000 1–28 days after ChAdOx1-S), 
cerebral venous thrombosis (3 per 100,000) and other venous thrombosis (2 per 
100,000).11 The randomised trials of ChAdOx1-S, reported no venous thrombotic 
events among 8597 participants who received the vaccine versus two among 
8581who received placebo.12 A Scottish study found a risk of of 1.13 (0.62–1.63) 
cases of idiopathic thrombocytopenic purpura per 100,000 after ChAdOx1-S. There 
was no clear evidence on other outcomes, although the number of post-vaccine events 
was small.13 Reporting of ICVT cases to the UK Medicines and Healthcare products 
Regulatory Agency (MHRA) identified more cases of ICVT with thrombocytopenia 
after ChAdOx1-S than the present study (44 up to 31st March 2021).14  
Healthcare systems planning to use ChAdOx1-S should balance the very small harms 
against the known benefits of the vaccine. For older populations, who are most 
vulnerable to COVID-19, we found no evidence of increased risk of any event with 
ChAdOx1-S. In younger populations, who have a lower morbidity and mortality due to 
COVID-19, other available vaccines might be prioritise, especially when the risk of 
COVID-19 is otherwise low. 
Our study has several limitations. First, identification of exposures, covariates and 
outcomes relies on the accuracy of data collected during routine healthcare. Additional 
data on results of laboratory and radiology investigations would have improved 
diagnostic coding, particularly for ascertainment of thrombocytopenia. Second, people 
who were not registered with an NHS GP (for example the homeless, recent 
immigrants, those using only private healthcare and those not eligible for NHS care) 
or who opted out of their data being provided to NHS Digital were excluded. Third, 
follow up ended on March 18th 2021, but a small number of events that occurred before 
this date may have been excluded because they had yet to be coded or the people 
affected were still in hospital. Analyses after this date will likely lead to overestimation 
of associations, because speciality societies recommended further investigations of 
mild symptoms in vaccinated populations. Fourth, our primary outcome used the 
primary reason for death or hospital admission, which improves the positive predictive 
value but may lead to an underestimation of incidence. This is necessary because 
historical non-incident events are frequently recorded in secondary positions. 
Analyses of events recorded in any position as fatal within 28 days were consistent 
with the primary analyses. Fifth, we did not address time-varying confounding, which 
can occur when factors which vary during follow up, such as admission to hospital, 
predict both vaccination and outcomes of interest. Sixth, comparison of adjusted and 
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unadjusted associations suggests that studies that do not adjust for a comprehensive 
range of potential confounders will overestimate the thrombotic effects of vaccination. 
However, adjusted associations in this study may still be biased by unmeasured 
confounding by patient characteristics that predict both vaccination and thromboses 
and that are difficult to ascertain in electronic health records. Examples include general 
health at the time of vaccination, and people at higher risk of thromboses (e.g. with 
end-stage diseases).15 There were slightly lower post-vaccination rates of the 
‘negative control’ outcome lower limb fracture in those aged ≥70 years, which implies 
that this degree of unmeasured confounding may affect results for thrombotic 
outcomes in that age group. 
Associations of vaccination with thromboses varied with age. This may be because in 
older people small increases in the risk of major thrombotic events after vaccination 
with ChAdOx1-S were more than offset by reductions in major thrombotic events 
(particularly PE) subsequent to COVID-19. By contrast, in younger people any 
increase in risk associated with ChAdOx1-S vaccine is less likely to be offset by a 
lower risk of COVID-associated thrombosis, because the chance of severe COVID 
disease is lower in younger than older individuals. 
Further analyses assessing the effects of other vaccines and the effects of second 
doses of these vaccines on thrombotic, neurological and cardiac complications will be 
important to inform vaccination programs. Access to data from radiology or laboratory 
systems (which in the UK will rely on regional rather than national data collection 
systems) will allow more comprehensive case ascertainment and more granular 
phenotyping. Such efforts are currently underway across the UK. 
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Table 1 Numbers of patients analysed and (in parentheses) risk per 100,000 of venous 
and arterial events and thrombocytopenia (TCP) during follow up, overall and 
according to age. 
Table 2 Numbers of events and incidence rates pre and post first vaccination. 
Incidence rate per 100,000 per annum (a) ChAdOx1-S (b) BNT162b2 vaccine 
FIGURE LEGENDS 
 
Figure 1 Adjusted Hazard ratios for all venous thromboses, intracranial venous 
thromboses, pulmonary embolism and deep vein thromboses after ChAdOx1-S or 
BNT162b2 vaccine.  
Figure 2 Adjusted hazard ratios for all arterial thromboses, myocardial infarction, 
ischaemic stroke and other arterial thromboses after ChAdOx1-S or BNT162b2 
vaccine.  
Figure 3 Adjusted hazard ratios for thrombocytopenia haemorrhagic stroke, 
mesenteric thrombosis, lower limb fracture after ChAdOx1-S or BNT162b2 vaccine 
SUPPLEMENTARY MATERIAL 
Protocol 
Supplementary table 1 Unadjusted, age-, sex- and region- adjusted, and fully 
adjusted hazard ratios for (a) ChAdOx1-S (b) BNT162b2 vaccine 
Supplementary table 2 Stratum specific estimates for (a) venous and (b) arterial 
events. 
Supplementary table 3. Characteristics of patient who had an ICVT event before and 
after vaccination. Only percentage are presented, as disclosure control does not allow 
numbers <5 to be released 
Supplementary figure 1: Cumulative frequency of vaccines of different types during 
follow up 
Supplementary figure 2: Adjusted hazard ratios for portal vein thrombosis, other 
venous events, and death after ChAdOx1-S or BNT162b2 vaccine  
Supplementary Figure 3 Hazard ratios for major (A) arterial and (B) venous 
thrombotic events, and (C) haematological events, other events and lower limb 
fractures recorded in any position in EHR 
Supplementary Figure 4: Hazard ratios for major (A) arterial and (B) venous 
thrombotic events, (C) haematological events, other events and fractures recorded in 
death record or in hospital record in first position followed by death <28 days 
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Table 1. Numbers of patients analysed (in parentheses) risk per 100,000 of venous and arterial events and thrombocytopenia (TCP), overall and according to age. 
 Overall Age, <70 Age, 70 
All Venous Arterial TCP All Venous Arterial TCP All Venous Arterial TCP 
N  46162942 20903 (45.3) 87251 (189) 1926 (4.2) 38744171 11835 (30.5) 38283 (98.8) 1167 (3.0) 7418771 9068 (122) 48968 (660) 759 (10.2) 
Sex 
Male 22765779 10358 (45.5) 51851 (228) 986 (4.3) 19425454 6406 (33.0) 26549 (137) 555 (2.9) 3340325 3952 (118) 25302 (757) 431 (12.9) 
Female 23397163 10545 (45.1) 35400 (151) 940 (4.0) 19318717 5429 (28.1) 11734 (60.7) 612 (3.2) 4078446 5116 (125) 23666 (580) 328 (8.0) 
Age 
18 - 29 8821973 781 (8.9) 400 (4.5) 143 (1.6) 8821973 781 (8.9) 400 (4.5) 143 (1.6)     
30 - 49 16131025 3544 (22.0) 6424 (39.8) 338 (2.1) 16131025 3544 (22.0) 6424 (39.8) 338 (2.1)     
50 - 69 13791173 7510 (54.5) 31459 (228) 686 (5.0) 13791173 7510 (54.5) 31459 (228) 686 (5.0)     
70 - 79 4674973 4820 (103) 22249 (476) 418 (8.9)     4674973 4820 (103) 22249 (476) 418 (8.9) 
80+ 2743798 4248 (155) 26719 (974) 341 (12.4)     2743798 4248 (155) 26719 (974) 341 (12.4) 
Ethnicity 
Asian or Asian British 3718442 599 (16.1) 5325 (143) 152 (4.1) 3467223 475 (13.7) 3378 (97.4) 125 (3.6) 251219 124 (49.4) 1947 (775) 27 (10.7) 
Black or Black British 1634470 654 (40.0) 2086 (128) 58 (3.5) 1525603 513 (33.6) 1384 (90.7) 45 (2.9) 108867 141 (130) 702 (645) 13 (11.9) 
Mixed 712534 182 (25.5) 642 (90.1) 22 (3.1) 682037 153 (22.4) 426 (62.5) 19 (2.8) 30497 29 (95.1) 216 (708) 3 (9.8) 
Other ethnic groups 1497133 217 (14.5) 1072 (71.6) 39 (2.6) 1427187 162 (11.4) 678 (47.5) 33 (2.3) 69946 55 (78.6) 394 (563) 6 (8.6) 
White 36446855 18995 (52.1) 77118 (212) 1643 (4.5) 29619868 10362 (35.0) 31821 (107) 939 (3.2) 6826987 8633 (126) 45297 (663) 704 (10.3) 
Unknown or missing 2153508 256 (11.9) 1008 (46.8) 12 (0.6) 2022253 170 (8.4) 596 (29.5) 6 (0.3) 131255 86 (65.5) 412 (314) 6 (4.6) 
Deprivation1 
1 - 2 9118746 4565 (50.1) 18830 (206) 365 (4.0) 8069275 3064 (38.0) 10493 (130) 272 (3.4) 1049471 1501 (143) 8337 (794) 93 (8.9) 
3 - 4 9567633 4105 (42.9) 17436 (182) 370 (3.9) 8273028 2454 (29.7) 8370 (101) 234 (2.8) 1294605 1651 (128) 9066 (700) 136 (10.5) 
5 - 6  9355549 4091 (43.7) 17642 (189) 392 (4.2) 7784840 2235 (28.7) 7263 (93.3) 221 (2.8) 1570709 1856 (118) 10379 (661) 171 (10.9) 
7 - 8 9076313 4146 (45.7) 16939 (187) 381 (4.2) 7362375 2128 (28.9) 6334 (86.0) 221 (3.0) 1713938 2018 (118) 10605 (619) 160 (9.3) 
9 - 10 8772902 3926 (44.8) 16024 (183) 406 (4.6) 7000538 1908 (27.3) 5602 (80.0) 210 (3.0) 1772364 2018 (114) 10422 (588) 196 (11.1) 
Smoking 
status 
Current 7814045 3079 (39.4) 16115 (206) 260 (3.3) 7287225 2492 (34.2) 11811 (162) 219 (3.0) 526820 587 (111) 4304 (817) 41 (7.8) 
Former 10623072 6930 (65.2) 31768 (299) 581 (5.5) 7826062 3233 (41.3) 11703 (150) 277 (3.5) 2797010 3697 (132) 20065 (717) 304 (10.9) 
Never 25722494 10667 (41.5) 38701 (150) 1053 (4.1) 21674974 5929 (27.4) 14346 (66.2) 643 (3.0) 4047520 4738 (117) 24355 (602) 410 (10.1) 
Medical 
history 
Stroke 727218 1020 (140) 21489 (2955) 104 (14.3) 286650 323 (113) 8147 (2842) 40 (14.0) 440568 697 (158) 13342 (3028) 64 (14.5) 
MI 1189182 1436 (121) 24212 (2036) 158 (13.3) 485506 436 (89.8) 10486 (2160) 46 (9.5) 703676 1000 (142) 13726 (1951) 112 (15.9) 
DVT or PE 603351 3263 (541) 4050 (671) 142 (23.5) 341788 1919 (561) 1377 (403) 76 (22.2) 261563 1344 (514) 2673 (1022) 66 (25.2) 
Thrombophilia 44593 146 (327) 202 (453) 23 (51.6) 38136 126 (330) 144 (378) 21 (55.1) 6457 20 (310) 58 (898) 2 (31.0) 
Coronavirus infection2  1284984 1131 (88.0) 4167 (324) 101 (7.9) 1124135 576 (51.2) 1642 (146) 63 (5.6) 160849 555 (345) 2525 (1570) 38 (23.6) 
Diabetes 4069412 3654 (89.8) 25595 (629) 423 (10.4) 2460649 1509 (61.3) 9949 (404) 205 (8.3) 1608763 2145 (133) 15646 (973) 218 (13.6) 
Depression 9516020 6272 (65.9) 24146 (254) 500 (5.3) 8040590 4077 (50.7) 12859 (160) 348 (4.3) 1475430 2195 (149) 11287 (765) 152 (10.3) 
Obesity 10918274 8863 (81.2) 31194 (286) 679 (6.2) 8757004 5430 (62.0) 15848 (181) 411 (4.7) 2161270 3433 (159) 15346 (710) 268 (12.4) 
Cancer 6609691 5674 (85.8) 17827 (270) 786 (11.9) 4854822 2583 (53.2) 4462 (91.9) 412 (8.5) 1754869 3091 (176) 13365 (762) 374 (21.3) 
COPD 1582366 2497 (158) 12323 (779) 182 (11.5) 714880 877 (123) 3839 (537) 76 (10.6) 867486 1620 (187) 8484 (978) 106 (12.2) 
Liver disease 230243 284 (123) 1069 (464) 97 (42.1) 173423 208 (120) 547 (315) 75 (43.2) 56820 76 (134) 522 (919) 22 (38.7) 
CKD 2934107 4467 (152) 25816 (880) 526 (17.9) 978886 1179 (120) 5164 (528) 200 (20.4) 1955221 3288 (168) 20652 (1056) 326 (16.7) 
Major surgery3 3995870 5407 (135) 24164 (605) 763 (19.1) 2773174 2735 (98.6) 9898 (357) 440 (15.9) 1222696 2672 (219) 14266 (1167) 323 (26.4) 
Dementia 524293 1127 (215) 6073 (1158) 45 (8.6) 48821 81 (166) 415 (850) 10 (20.5) 475472 1046 (220) 5658 (1190) 35 (7.4) 
Medications 
Antiplatelet 2510382 2814 (112) 36415 (1451) 218 (8.7) 1000010 747 (74.7) 15556 (1556) 65 (6.5) 1510372 2067 (137) 20859 (1381) 153 (10.1) 
BP lowering 8589860 7969 (92.8) 55462 (646) 777 (9.0) 4286561 2779 (64.8) 20579 (480) 305 (7.1) 4303299 5190 (121) 34883 (811) 472 (11.0) 
Lipid lowering 6808408 5796 (85.1) 47859 (703) 564 (8.3) 3212600 1878 (58.5) 19543 (608) 194 (6.0) 3595808 3918 (109) 28316 (787) 370 (10.3) 
Anticoagulant 1338585 2278 (170) 12758 (953) 205 (15.3) 381588 1144 (300) 2773 (727) 57 (14.9) 956997 1134 (118) 9985 (1043) 148 (15.5) 
Oral contraceptive 622529 138 (22.2) 42 (6.7) 8 (1.3) 622529 138 (22.2) 42 (6.7) 8 (1.3)     
HRT 540722 213 (39.4) 516 (95.4) 16 (3.0) 501957 185 (36.9) 368 (73.3) 14 (2.8) 38765 28 (72.2) 148 (382) 2 (5.2) 
Number of 
diagnoses 
0 36455307 12200 (33.5) 38617 (106) 980 (2.7) 31819272 7612 (23.9) 18316 (57.6) 643 (2.0) 4636035 4588 (99.0) 20301 (438) 337 (7.3) 
1 - 5 9573068 8422 (88.0) 46012 (481) 925 (9.7) 6872479 4137 (60.2) 19183 (279) 515 (7.5) 2700589 4285 (159) 26829 (993) 410 (15.2) 
6+ 134567 281 (209) 2622 (1948) 21 (15.6) 52420 86 (164) 784 (1496) 9 (17.2) 82147 195 (237) 1838 (2237) 12 (14.6) 
Number of 
medications 
0 22970920 3679 (16.0) 9629 (41.9) 321 (1.4) 22122043 3143 (14.2) 7258 (32.8) 290 (1.3) 848877 536 (63.1) 2371 (279) 31 (3.7) 
1 - 5 20875516 12872 (61.7) 56255 (269) 1210 (5.8) 15618756 7203 (46.1) 25416 (163) 713 (4.6) 5256760 5669 (108) 30839 (587) 497 (9.5) 
6+ 2316506 4352 (188) 21367 (922) 395 (17.1) 1003372 1489 (148) 5609 (559) 164 (16.3) 1313134 2863 (218) 15758 (1200) 231 (17.6) 
 
1 Index of Multiple Deprivation deciles where 1 indicates least deprived and 10 indicates most deprived; 2 After 31/12/2019 and prior to 08/12/2020; 3 In the last year. 
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Table 2(a) Numbers and incidence rates pre-, post-first ChAdOx1-S. Incidence rate per 100,000 per annum. Disclosure control prevents presentation of n>5  
  Pre vaccination or unvaccinated Post vaccination ≤28 days Post vaccination >28 days 
Outcome Age N (events) Incidence rate (95% 
CI) 
N (events) Incidence rate (95% CI) N (events) Incidence rate (95% 
CI) All venous All 14769 140.7 (138.5–143.0) 2006 309.0 (295.8–322.9) 995 382.6 (359.6–407.2) 
 <70 9892 104.3 (102.2–106.3) 902 219.5 (205.7–234.3) 234 240.6 (211.7–273.5) 
 ≥70 4877 484.5 (471.1–498.3) 1104 463.4 (436.9–491.6) 761 467.5 (435.4–501.9) 
Intracranial venous thrombosis All 207 1.97 (1.72–2.26) 27 4.16 (2.85–6.06) 9 3.46 (1.80–6.65) 
 <70 188 1.98 (1.72–2.29) 22 5.35 (3.52–8.13) <10 5.14 (2.14–12.35) 
 ≥70 19 1.89 (1.20–2.96) 5 2.10 (0.87–5.04) <5 2.45 (0.92–6.54) 
Portal vein thrombosis All 121 1.15 (0.96–1.38) 14 2.16 (1.28–3.64) 9 3.46 (1.80–6.65) 
 <70 98 1.03 (0.85–1.26) 9 2.19 (1.14–4.21) <5 2.06 (0.51–8.22) 
 ≥70 23 2.28 (1.52–3.44) 5 2.10 (0.87–5.04) <10 4.30 (2.05–9.01) 
Pulmonary embolism All 8473 80.7 (79.0–82.5) 1203 185.3 (175.1–196.1) 587 225.7 (208.1–244.7) 
 <70 5399 56.9 (55.4–58.4) 515 125.3 (114.9–136.6) 134 137.8 (116.3–163.2) 
 ≥70 3074 305.3 (294.7–316.3) 688 288.7 (267.9–311.1) 453 278.2 (253.7–305.0) 
Deep vein thrombosis All 5664 54.0 (52.6–55.4) 739 113.8 (105.9–122.3) 374 143.8 (129.9–159.1) 
 <70 3971 41.9 (40.6–43.2) 345 83.9 (75.5–93.3) 90 92.5 (75.3–113.8) 
 ≥70 1693 168.1 (160.3–176.3) 394 165.3 (149.8–182.5) 284 174.4 (155.2–195.9) 
Other All 459 4.37 (3.99–4.79) 51 7.85 (5.97–10.33) 30 11.5 (8.1–16.5) 
 <70 359 3.78 (3.41–4.20) 34 8.27 (5.91–11.58) 9 9.25 (4.81–17.78) 
 ≥70 100 9.93 (8.16–12.08) 17 7.13 (4.43–11.47) 21 12.9 (8.4–19.8) 
All arterial All 57602 549.1 (544.7–553.6) 8256 1274.4 (1247.2–1302.1) 4634 1787.0 (1736.3–1839.2) 
 <70 31396 331.0 (327.4–334.7) 2993 729.4 (703.8–756.0) 755 777.4 (723.9–834.9) 
 ≥70 26206 2607.7 (2576.3–2639.5) 5263 2215.7 (2156.7–2276.4) 3879 2391.5 (2317.4–2467.9) 
Myocardial infarction All 28134 268.1 (265.0–271.3) 3814 587.9 (569.6–606.9) 2050 788.9 (755.5–823.8) 
 <70 17341 182.8 (180.1–185.5) 1628 396.4 (377.6–416.2) 363 373.4 (336.9–413.9) 
 ≥70 10793 1072.7 (1052.6–1093.1) 2186 918.3 (880.6–957.6) 1687 1037.3 (988.9–1088.0) 
Ischaemic stroke All 28639 272.9 (269.8–276.1) 4334 668.2 (648.6–688.4) 2539 977.6 (940.3–1016.4) 
(ischaemic, unknown, retinal and spinal) <70 13505 142.4 (140.0–144.8) 1309 318.7 (301.9–336.4) 377 387.8 (350.6–429.0) 
 ≥70 15134 1504.7 (1480.9–1528.9) 3025 1271.6 (1227.1–1317.7) 2162 1330.4 (1275.5–1387.7) 
Other arterial All 1308 12.5 (11.8–13.2) 189 29.1 (25.2–33.6) 98 37.7 (30.9–45.9) 
 <70 775 8.17 (7.61–8.76) 82 19.9 (16.1–24.8) 22 22.6 (14.9–34.3) 
 ≥70 533 52.9 (48.6–57.6) 107 44.9 (37.1–54.2) 76 46.6 (37.3–58.4) 
Other        
Disseminated intravascular coagulation All 13 0.12 (0.07–0.21) <5 0.46 (0.15–1.43) <5 - 
 <70 5 0.05 (0.02–0.13) <5 0.49 (0.12–1.95) <5 - 
 ≥70 8 0.79 (0.40–1.59) <5 0.42 (0.06–2.98) <5 - 
Thrombotic thrombocytopenic purpura All 70 0.67 (0.53–0.84) <5 0.62 (0.23–1.64) <5 0.77 (0.19–3.07) 
 <70 64 0.67 (0.53–0.86) <5 0.73 (0.24–2.26) <5 2.06 (0.51–8.22) 
 ≥70 6 0.60 (0.27–1.33) <5 0.42 (0.06–2.98) <5 - 
Any thrombocytopenia All 1357 12.9 (12.3–13.6) 200 30.8 (26.8–35.4) 89 34.2 (27.8–42.1) 
 <70 915 9.64 (9.04–10.29) 124 30.2 (25.3–36.0) 41 42.1 (31.0–57.2) 
 ≥70 442 43.9 (40.0–48.2) 76 31.9 (25.5–39.9) 48 29.5 (22.2–39.1) 
Haemorrhagic stroke All 3747 35.7 (34.6–36.9) 487 75.0 (68.6–82.0) 289 111.1 (99.0–124.6) 
(intra-cerebral or subarachnoid) <70 2028 21.4 (20.5–22.3) 157 38.2 (32.7–44.7) 45 46.3 (34.5–62.0) 
 ≥70 1719 170.7 (162.8–179.0) 330 138.4 (124.3–154.2) 244 149.8 (132.1–169.8) 
Mesenteric thrombosis All 1170 11.1 (10.5–11.8) 171 26.3 (22.7–30.6) 109 41.9 (34.7–50.5) 
 <70 531 5.60 (5.14–6.09) 56 13.6 (10.5–17.7) 20 20.6 (13.3–31.9) 
 ≥70 639 63.5 (58.7–68.6) 115 48.2 (40.2–57.9) 89 54.6 (44.4–67.2) 
Lower limb fracture All 18347 174.9 (172.3–177.4) 2657 409.4 (394.2–425.3) 1632 628.0 (598.3–659.2) 
 <70 8732 92.0 (90.1–94.0) 539 131.2 (120.5–142.7) 155 159.4 (136.2–186.5) 
 ≥70 9615 955.8 (936.9–975.1) 2118 890.0 (852.9–928.7) 1477 908.3 (863.2–955.9) 
Death All 123580 1177.5 (1170.9–1184.1) 16192 2493.1 (2455.0–2531.8) 11738 4510.6 (4429.7–4592.9) 
 <70 29802 314.1 (310.5–317.7) 1940 471.9 (451.4–493.4) 897 922.0 (863.6–984.3) 
 ≥70 93778 9312.7 (9253.3–9372.5) 14252 5978.2 (5880.8–6077.1) 10841 6653.3 (6529.2–6779.7) 
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Table 2(b) Numbers and incidence rates pre-, post-first BNT162b2. Incidence rate per 100,000 per annum. Disclosure control prevents presentation of n>5  
  Pre vaccination or unvaccinated Post vaccination ≤28 days Post vaccination >28 days 
Outcome Age N (events) Incidence rate (95% 
CI) 
N (events) Incidence rate (95% 
CI) 
N (events) Incidence rate (95% 
CI) All venous All 14769 140.7 (138.5–143.0) 1546 250.1 (237.9–262.9) 1587 287.0 (273.2–301.5) 
 <70 9892 104.3 (102.2–106.3) 548 154.9 (142.4–168.4) 259 110.8 (98.1–125.2) 
 ≥70 4877 484.5 (471.1–498.3) 998 377.7 (355.0–401.9) 1328 415.9 (394.1–438.9) 
Intracranial venous thrombosis All 207 1.97 (1.72–2.26) 13 2.10 (1.22–3.62) 6 1.08 (0.49–2.41) 
 <70 188 1.98 (1.72–2.29) 5 1.41 (0.59–3.39) <5 1.28 (0.41–3.98) 
 ≥70 19 1.89 (1.20–2.96) 8 3.03 (1.51–6.05) <5 0.94 (0.30–2.91) 
Portal vein thrombosis All 121 1.15 (0.96–1.38) 5 0.81 (0.34–1.94) 12 2.17 (1.23–3.82) 
 <70 98 1.03 (0.85–1.26) <5 0.56 (0.14–2.26) 6 2.57 (1.15–5.71) 
 ≥70 23 2.28 (1.52–3.44) <5 1.13 (0.37–3.52) 6 1.88 (0.84–4.18) 
Pulmonary embolism All 8473 80.7 (79.0–82.5) 928 150.1 (140.8–160.1) 955 172.7 (162.1–184.0) 
 <70 5399 56.9 (55.4–58.4) 306 86.5 (77.3–96.7) 141 60.3 (51.2–71.2) 
 ≥70 3074 305.3 (294.7–316.3) 622 235.3 (217.6–254.6) 814 254.8 (237.9–273.0) 
Deep vein thrombosis All 5664 54.0 (52.6–55.4) 555 89.8 (82.6–97.6) 590 106.7 (98.4–115.6) 
 <70 3971 41.9 (40.6–43.2) 213 60.2 (52.6–68.8) 103 44.1 (36.3–53.5) 
 ≥70 1693 168.1 (160.3–176.3) 342 129.4 (116.4–143.9) 487 152.4 (139.5–166.6) 
Other All 459 4.37 (3.99–4.79) 55 8.89 (6.83–11.59) 39 7.05 (5.15–9.65) 
 <70 359 3.78 (3.41–4.20) 28 7.91 (5.46–11.46) 13 5.56 (3.23–9.58) 
 ≥70 100 9.93 (8.16–12.08) 27 10.2 (7.0–14.9) 26 8.14 (5.54–11.95) 
All arterial All 57602 549.1 (544.7–553.6) 7960 1289.8 (1261.7–1318.4) 8799 1594.8 (1561.8–1628.5) 
 <70 31396 331.0 (327.4–334.7) 2263 640.2 (614.4–667.2) 876 375.1 (351.1–400.8) 
 ≥70 26206 2607.7 (2576.3–2639.5) 5697 2160.4 (2105.0–2217.2) 7923 2490.0 (2435.7–2545.4) 
Myocardial infarction All 28134 268.1 (265.0–271.3) 3722 602.5 (583.4–622.2) 4023 728.0 (705.9–750.9) 
 <70 17341 182.8 (180.1–185.5) 1285 363.3 (344.0–383.7) 489 209.3 (191.6–228.7) 
 ≥70 10793 1072.7 (1052.6–1093.1) 2437 922.9 (886.9–960.2) 3534 1107.9 (1072.0–1145.1) 
Ischaemic stroke All 28639 272.9 (269.8–276.1) 4143 670.6 (650.5–691.4) 4702 851.2 (827.2–875.9) 
(ischaemic, unknown, retinal and spinal) <70 13505 142.4 (140.0–144.8) 949 268.2 (251.7–285.9) 369 157.9 (142.6–174.9) 
 ≥70 15134 1504.7 (1480.9–1528.9) 3194 1209.9 (1168.6–1252.6) 4333 1359.3 (1319.4–1400.4) 
Other arterial All 1308 12.5 (11.8–13.2) 156 25.2 (21.6–29.5) 167 30.2 (25.9–35.1) 
 <70 775 8.17 (7.61–8.76) 46 13.0 (9.7–17.3) 26 11.1 (7.6–16.3) 
 ≥70 533 52.9 (48.6–57.6) 110 41.6 (34.5–50.2) 141 44.1 (37.4–52.0) 
Other        
Disseminated intravascular coagulation All 13 0.12 (0.07–0.21) <5 0.32 (0.08–1.29) <5 0.36 (0.09–1.45) 
 <70 5 0.05 (0.02–0.13) <5 0.28 (0.04–2.01) <5 - 
 ≥70 8 0.79 (0.40–1.59) <5 0.38 (0.05–2.69) <5 0.63 (0.16–2.50) 
Thrombotic thrombocytopenic purpura All 70 0.67 (0.53–0.84) <5 0.65 (0.24–1.72) <5 0.36 (0.09–1.45) 
 <70 64 0.67 (0.53–0.86) <5 0.85 (0.27–2.63) <5 0.86 (0.21–3.42) 
 ≥70 6 0.60 (0.27–1.33) <5 0.38 (0.05–2.69) <5 - 
Any thrombocytopenia All 1357 12.9 (12.3–13.6) 136 22.0 (18.6–26.0) 144 26.0 (22.1–30.6) 
 <70 915 9.64 (9.04–10.29) 55 15.5 (11.9–20.2) 32 13.7 (9.7–19.4) 
 ≥70 442 43.9 (40.0–48.2) 81 30.6 (24.6–38.1) 112 35.1 (29.1–42.2) 
Haemorrhagic stroke All 3747 35.7 (34.6–36.9) 440 71.2 (64.8–78.1) 579 104.7 (96.5–113.5) 
(intra-cerebral or subarachnoid) <70 2028 21.4 (20.5–22.3) 93 26.3 (21.4–32.2) 55 23.5 (18.1–30.7) 
 ≥70 1719 170.7 (162.8–179.0) 347 131.3 (118.2–145.8) 524 164.0 (150.6–178.7) 
Mesenteric thrombosis All 1170 11.1 (10.5–11.8) 161 26.0 (22.3–30.4) 217 39.2 (34.3–44.8) 
 <70 531 5.60 (5.14–6.09) 28 7.91 (5.46–11.46) 18 7.70 (4.85–12.22) 
 ≥70 639 63.5 (58.7–68.6) 133 50.3 (42.4–59.6) 199 62.3 (54.2–71.6) 
Lower limb fracture All 18347 174.9 (172.3–177.4) 2573 416.2 (400.5–432.6) 3176 574.6 (554.9–594.9) 
 <70 8732 92.0 (90.1–94.0) 443 125.2 (114.0–137.4) 228 97.6 (85.7–111.1) 
 ≥70 9615 955.8 (936.9–975.1) 2130 806.2 (772.7–841.2) 2948 923.9 (891.2–957.9) 
Death All 123580 1177.5 (1170.9–1184.1) 9117 1474.4 (1444.4–1504.9) 13935 2518.7 (2477.3–2560.9) 
 <70 29802 314.1 (310.5–317.7) 775 218.9 (204.0–234.9) 531 227.2 (208.7–247.4) 
 ≥70 93778 9312.7 (9253.3–9372.5) 8342 3155.6 (3088.6–3224.1) 13404 4194.8 (4124.4–4266.4) 
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Age<70, 11835 events Age≥70, 9068 events
Men
Age<70, 6406 events Age≥70, 3952 events
Women
Age<70, 5429 events Age≥70, 5116 events
ChAdOx1-S
BNT162b2


















































































Age<70, 223 events Age≥70, 39 events
Men
Age<70, 88 events Age≥70, 10 events
Women
Age<70, 135 events Age≥70, 29 events
ChAdOx1-S
BNT162b2


















































































Age<70, 6495 events Age≥70, 5651 events
Men
Age<70, 3505 events Age≥70, 2524 events
Women
Age<70, 2990 events Age≥70, 3127 events
ChAdOx1-S
BNT162b2


















































































Age<70, 4722 events Age≥70, 3200 events
Men
Age<70, 2598 events Age≥70, 1320 events
Women
Age<70, 2124 events Age≥70, 1880 events
ChAdOx1-S
BNT162b2
Hazard Ratios venous event update – fully adjusted (using backwards selection)
HR  
(95% CI) 
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Age<70, 38283 events Age≥70, 48968 events
Men
Age<70, 26549 events Age≥70, 25302 events
Women
Age<70, 11734 events Age≥70, 23666 events
ChAdOx1-S
BNT162b2


















































































Age<70, 21106 events Age≥70, 20637 events
Men
Age<70, 15790 events Age≥70, 11898 events
Women
Age<70, 5316 events Age≥70, 8739 events
ChAdOx1-S
BNT162b2


















































































Age<70, 16509 events Age≥70, 27848 events
Men
Age<70, 10317 events Age≥70, 13127 events
Women
Age<70, 6192 events Age≥70, 14721 events
ChAdOx1-S
BNT162b2


















































































Age<70, 951 events Age≥70, 967 events
Men
Age<70, 636 events Age≥70, 534 events
Women
Age<70, 315 events Age≥70, 433 events
ChAdOx1-S
BNT162b2
Hazard Ratios venous event update – fully adjusted (using backwards selection)
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Age<70, 1167 events Age≥70, 759 events
Men
Age<70, 555 events Age≥70, 431 events
Women
Age<70, 612 events Age≥70, 328 events
ChAdOx1-S
BNT162b2


















































































Age<70, 2378 events Age≥70, 3164 events
Men
Age<70, 1320 events Age≥70, 1390 events
Women
Age<70, 1058 events Age≥70, 1774 events
ChAdOx1-S
BNT162b2


















































































Age<70, 653 events Age≥70, 1175 events
Men
Age<70, 298 events Age≥70, 402 events
Women
Age<70, 355 events Age≥70, 773 events
ChAdOx1-S
BNT162b2


















































































Age<70, 10097 events Age≥70, 18288 events
Men
Age<70, 4459 events Age≥70, 5080 events
Women
Age<70, 5638 events Age≥70, 13208 events
ChAdOx1-S
BNT162b2
Hazard Ratios venous event update – fully adjusted (using backwards selection)
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SUPPLEMENTARY TABLES AND FIGURES 
Supplementary Table 1: Hazard ratios (95% CIs) for thrombotic and other outcomes 1-28 and >28 days post-vaccination, compared with pre-vaccination rates. All analyses were stratified on 
geographical region (A) ChAdOx1-S vaccine (B) BNT162b2 vaccine 
Outcome Age Sex 1-28 days post-vaccination >28 days post vaccination s 
   Unadjusted1 Age and sex 
adjusted2 
Fully adjusted3 Unadjusted1 Age and sex adjusted2 Fully adjusted3 
(A) ChAdOx1-S vaccine         
All venous events <70 Overall 2.33 (2.16–2.51) 1.32 (1.22–1.43) 0.97 (0.90–1.05) 2.74 (2.39–3.14) 1.60 (1.38–1.84) 0.94 (0.81–1.08) 
  Men 2.68 (2.41–2.97) 1.33 (1.19–1.49) 1.04 (0.93–1.16) 3.13 (2.54–3.84) 1.52 (1.23–1.89) 0.97 (0.78–1.20) 
  Women 2.08 (1.87–2.31) 1.31 (1.17–1.47) 0.96 (0.85–1.07) 2.56 (2.13–3.07) 1.67 (1.38–2.02) 1.02 (0.84–1.23) 
 ≥70 Overall 0.65 (0.59–0.72) 0.64 (0.59–0.70) 0.58 (0.53–0.63) 0.67 (0.59–0.76) 0.58 (0.52–0.65) 0.49 (0.44–0.55) 
  Men 0.65 (0.56–0.76) 0.65 (0.56–0.74) 0.59 (0.51–0.68) 0.70 (0.58–0.84) 0.63 (0.53–0.75) 0.55 (0.46–0.65) 
  Women 0.65 (0.58–0.74) 0.64 (0.56–0.71) 0.57 (0.50–0.64) 0.64 (0.54–0.76) 0.54 (0.47–0.64) 0.45 (0.39–0.53) 
Intracranial venous thrombosis <70 Overall 2.81 (1.70–4.64) 2.99 (1.75–5.09) 2.27 (1.33–3.88) 2.37 (0.91–6.12) 2.47 (0.95–6.42) 1.72 (0.66–4.49) 
  Men 2.72 (1.15–6.39) 2.58 (0.99–6.74) 2.06 (0.79–5.37) 3.43 (0.74–15.87) 3.37 (0.71–15.90) 2.40 (0.53–10.86) 
  Women 2.69 (1.45–5.00) 3.27 (1.74–6.17) 2.24 (1.17–4.31) 1.75 (0.52–5.93) 2.14 (0.63–7.22) 1.47 (0.43–5.04) 
 ≥70 Overall 0.62 (0.17–2.23) 0.65 (0.19–2.21) 0.67 (0.20–2.18) 1.35 (0.13–13.46) 1.13 (0.14–9.20) 1.11 (0.14–9.02) 
  Men 10.8 (3.3–35.8) 8.99 (2.75–29.42) 10.1 (2.7–38.5) - - - 
  Women 0.27 (0.05–1.42) 0.29 (0.06–1.43) 0.28 (0.06–1.34) 0.87 (0.10–7.32) 0.82 (0.11–6.24) 0.76 (0.10–5.70) 
Portal vein thrombosis <70 Overall 2.49 (1.20–5.14) 1.56 (0.72–3.40) 1.00 (0.24–4.15) 2.76 (0.73–10.51) 1.99 (0.53–7.52) 1.00 (0.06–18.18) 
  Men 3.38 (1.40–8.17) 1.95 (0.76–5.02) 1.22 (0.48–3.08) 3.55 (0.52–24.13) 2.16 (0.32–14.52) 0.98 (0.14–6.75) 
  Women 1.74 (0.48–6.26) 1.06 (0.28–4.07) 0.72 (0.18–2.86) 2.39 (0.37–15.53) 1.57 (0.24–10.12) 0.86 (0.12–6.28) 
 ≥70 Overall 0.66 (0.11–4.06) 0.67 (0.10–4.24) 0.61 (0.10–3.71) 2.72 (0.49–15.02) 3.00 (0.48–18.99) 2.61 (0.41–16.52) 
  Men 0.43 (0.09–2.09) 0.42 (0.08–2.15) 0.37 (0.07–1.90) 8.60 (2.33–31.70) 7.99 (1.93–33.03) 7.99 (2.03–31.38) 
  Women 0.92 (0.06–13.23) 0.92 (0.06–13.99) 0.82 (0.06–11.05) 0.87 (0.12–6.02) 0.95 (0.12–7.39) 0.86 (0.11–6.92) 
Pulmonary embolism <70 Overall 2.54 (2.30–2.80) 1.28 (1.15–1.43) 0.95 (0.85–1.05) 3.12 (2.61–3.73) 1.63 (1.34–1.96) 0.95 (0.79–1.15) 
  Men 2.83 (2.46–3.24) 1.27 (1.09–1.48) 1.01 (0.87–1.17) 3.32 (2.52–4.38) 1.43 (1.07–1.91) 0.92 (0.69–1.23) 
  Women 2.35 (2.04–2.70) 1.30 (1.12–1.52) 0.95 (0.82–1.10) 3.09 (2.44–3.92) 1.81 (1.41–2.32) 1.09 (0.85–1.41) 
 ≥70 Overall 0.62 (0.55–0.70) 0.60 (0.54–0.68) 0.54 (0.48–0.61) 0.61 (0.52–0.72) 0.54 (0.46–0.62) 0.45 (0.39–0.53) 
  Men 0.63 (0.52–0.75) 0.62 (0.52–0.74) 0.57 (0.47–0.67) 0.63 (0.50–0.79) 0.57 (0.46–0.70) 0.49 (0.40–0.62) 
  Women 0.61 (0.52–0.72) 0.59 (0.51–0.69) 0.53 (0.45–0.61) 0.60 (0.48–0.75) 0.51 (0.42–0.63) 0.43 (0.35–0.53) 
Deep vein thrombosis <70 Overall 2.08 (1.85–2.34) 1.34 (1.18–1.52) 0.99 (0.87–1.12) 2.37 (1.90–2.96) 1.58 (1.25–1.99) 0.97 (0.77–1.22) 
  Men 2.61 (2.22–3.07) 1.48 (1.25–1.76) 1.15 (0.97–1.36) 2.85 (2.04–3.98) 1.62 (1.14–2.29) 1.06 (0.75–1.50) 
  Women 1.67 (1.40–2.00) 1.21 (1.00–1.46) 0.90 (0.75–1.09) 2.12 (1.57–2.86) 1.57 (1.15–2.13) 1.02 (0.75–1.40) 
 ≥70 Overall 0.73 (0.62–0.86) 0.71 (0.61–0.83) 0.63 (0.54–0.74) 0.71 (0.57–0.88) 0.62 (0.51–0.75) 0.51 (0.42–0.62) 
  Men 0.72 (0.56–0.94) 0.71 (0.55–0.91) 0.63 (0.49–0.81) 0.77 (0.56–1.06) 0.70 (0.51–0.95) 0.58 (0.42–0.79) 
  Women 0.73 (0.59–0.90) 0.72 (0.59–0.87) 0.64 (0.53–0.77) 0.67 (0.51–0.88) 0.57 (0.45–0.73) 0.47 (0.37–0.60) 
Other <70 Overall 2.48 (1.70–3.62) 1.60 (1.06–2.40) 1.02 (0.69–1.52) 3.04 (1.54–6.00) 2.04 (1.01–4.09) 0.94 (0.47–1.91) 
  Men 2.61 (1.51–4.53) 1.45 (0.79–2.64) 1.02 (0.57–1.83) 3.17 (1.13–8.90) 1.74 (0.60–5.05) 0.89 (0.31–2.58) 
  Women 2.38 (1.42–4.00) 1.74 (1.01–2.98) 1.12 (0.65–1.91) 3.15 (1.29–7.73) 2.40 (0.97–5.96) 1.26 (0.50–3.17) 
 ≥70 Overall 0.46 (0.21–1.01) 0.46 (0.21–0.99) 0.43 (0.20–0.92) 1.13 (0.50–2.54) 1.03 (0.48–2.21) 0.93 (0.42–2.03) 
  Men 0.38 (0.11–1.30) 0.39 (0.12–1.31) 0.33 (0.10–1.08) 1.10 (0.36–3.39) 1.02 (0.34–3.04) 0.79 (0.26–2.36) 
  Women 0.52 (0.19–1.44) 0.51 (0.20–1.36) 0.50 (0.19–1.32) 1.16 (0.37–3.63) 1.03 (0.36–2.98) 0.98 (0.33–2.94) 
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   Unadjusted1 Age and sex 
adjusted2 
Fully adjusted3 Unadjusted1 Age and sex adjusted2 Fully adjusted3 
All arterial events <70 Overall 3.02 (2.90–3.14) 1.25 (1.20–1.31) 0.90 (0.86–0.95) 3.55 (3.29–3.83) 1.57 (1.45–1.70) 0.91 (0.84–1.00) 
  Men 3.42 (3.26–3.60) 1.26 (1.20–1.34) 0.91 (0.86–0.96) 4.70 (4.27–5.17) 1.66 (1.50–1.84) 0.96 (0.86–1.07) 
  Women 2.96 (2.76–3.18) 1.24 (1.14–1.34) 0.93 (0.86–1.00) 3.30 (2.90–3.75) 1.43 (1.25–1.64) 0.88 (0.77–1.02) 
 ≥70 Overall 0.89 (0.85–0.93) 0.84 (0.80–0.87) 0.76 (0.73–0.79) 1.03 (0.97–1.10) 0.83 (0.78–0.87) 0.72 (0.68–0.77) 
  Men 0.90 (0.85–0.96) 0.87 (0.82–0.92) 0.78 (0.74–0.83) 1.06 (0.97–1.16) 0.89 (0.82–0.96) 0.78 (0.71–0.85) 
  Women 0.88 (0.82–0.94) 0.80 (0.76–0.85) 0.73 (0.69–0.78) 1.02 (0.93–1.12) 0.77 (0.71–0.83) 0.68 (0.62–0.74) 
Myocardial infarction <70 Overall 2.85 (2.70–3.01) 1.24 (1.17–1.32) 0.88 (0.83–0.94) 2.93 (2.63–3.26) 1.40 (1.24–1.56) 0.83 (0.73–0.93) 
  Men 3.23 (3.02–3.44) 1.25 (1.17–1.35) 0.89 (0.83–0.95) 3.52 (3.08–4.03) 1.33 (1.15–1.53) 0.78 (0.68–0.90) 
  Women 2.93 (2.63–3.26) 1.22 (1.09–1.38) 0.92 (0.82–1.04) 3.56 (2.95–4.29) 1.58 (1.29–1.92) 1.01 (0.82–1.24) 
 ≥70 Overall 0.86 (0.80–0.92) 0.83 (0.78–0.88) 0.76 (0.71–0.81) 0.97 (0.89–1.07) 0.83 (0.76–0.90) 0.74 (0.68–0.81) 
  Men 0.88 (0.80–0.96) 0.85 (0.78–0.93) 0.77 (0.71–0.84) 0.96 (0.84–1.09) 0.84 (0.74–0.94) 0.73 (0.64–0.82) 
  Women 0.85 (0.76–0.94) 0.80 (0.72–0.88) 0.76 (0.69–0.84) 1.03 (0.90–1.19) 0.82 (0.72–0.93) 0.78 (0.68–0.88) 
Ischaemic stroke4 <70 Overall 3.21 (3.02–3.41) 1.25 (1.17–1.34) 0.90 (0.84–0.96) 4.36 (3.91–4.86) 1.76 (1.56–1.98) 0.94 (0.84–1.07) 
  Men 3.73 (3.44–4.05) 1.28 (1.17–1.40) 0.91 (0.83–0.99) 6.58 (5.73–7.57) 2.14 (1.84–2.49) 1.12 (0.96–1.31) 
  Women 2.91 (2.64–3.20) 1.21 (1.09–1.35) 0.90 (0.81–1.00) 3.10 (2.59–3.71) 1.32 (1.09–1.59) 0.77 (0.63–0.94) 
 ≥70 Overall 0.92 (0.87–0.98) 0.85 (0.81–0.90) 0.77 (0.73–0.82) 1.08 (0.99–1.18) 0.83 (0.77–0.90) 0.72 (0.67–0.78) 
  Men 0.94 (0.85–1.03) 0.89 (0.82–0.96) 0.81 (0.74–0.88) 1.14 (1.01–1.30) 0.93 (0.83–1.04) 0.82 (0.73–0.92) 
  Women 0.92 (0.84–1.00) 0.82 (0.77–0.89) 0.75 (0.69–0.80) 1.04 (0.92–1.17) 0.76 (0.68–0.84) 0.66 (0.59–0.73) 
Other arterial <70 Overall 3.18 (2.48–4.07) 1.24 (0.93–1.64) 0.82 (0.63–1.07) 4.20 (2.62–6.73) 1.68 (0.99–2.86) 0.77 (0.46–1.30) 
  Men 3.17 (2.29–4.40) 1.05 (0.73–1.51) 0.75 (0.53–1.07) 5.56 (3.07–10.06) 1.66 (0.86–3.20) 0.89 (0.47–1.69) 
  Women 3.67 (2.51–5.37) 1.59 (1.03–2.46) 1.04 (0.68–1.59) 3.60 (1.64–7.91) 1.74 (0.73–4.18) 0.83 (0.35–2.01) 
 ≥70 Overall 0.44 (0.33–0.59) 0.45 (0.34–0.59) 0.41 (0.31–0.53) 0.55 (0.38–0.79) 0.49 (0.35–0.70) 0.44 (0.31–0.63) 
  Men 0.46 (0.31–0.67) 0.45 (0.31–0.66) 0.42 (0.29–0.61) 0.61 (0.35–1.05) 0.56 (0.33–0.95) 0.51 (0.30–0.87) 
  Women 0.43 (0.28–0.66) 0.44 (0.30–0.67) 0.39 (0.26–0.59) 0.51 (0.30–0.86) 0.44 (0.27–0.71) 0.38 (0.23–0.62) 
Haematological events         
Any thrombocytopenia <70 Overall 4.85 (3.87–6.07) 3.00 (2.34–3.85) 1.71 (1.35–2.16) 7.48 (5.31–10.53) 4.68 (3.24–6.77) 1.69 (1.16–2.46) 
  Men 6.47 (4.62–9.06) 3.52 (2.42–5.13) 1.85 (1.30–2.63) 13.2 (8.1–21.4) 6.84 (3.99–11.73) 2.02 (1.18–3.44) 
  Women 3.81 (2.80–5.17) 2.65 (1.89–3.71) 1.95 (1.40–2.72) 4.59 (2.78–7.58) 3.34 (1.98–5.64) 2.08 (1.22–3.54) 
 ≥70 Overall 0.92 (0.65–1.29) 0.87 (0.63–1.22) 0.79 (0.56–1.10) 1.14 (0.66–1.95) 0.99 (0.59–1.65) 0.84 (0.50–1.41) 
  Men 0.84 (0.53–1.32) 0.79 (0.50–1.22) 0.68 (0.43–1.06) 1.37 (0.64–2.91) 1.17 (0.57–2.38) 0.92 (0.45–1.90) 
  Women 1.04 (0.62–1.75) 0.99 (0.61–1.63) 0.93 (0.56–1.54) 1.02 (0.46–2.24) 0.88 (0.42–1.85) 0.80 (0.38–1.70) 
Other events         
Haemorrhagic stroke5 <70 Overall 2.25 (1.88–2.69) 1.05 (0.86–1.27) 1.00 (0.73–1.37) 2.87 (2.10–3.92) 1.39 (1.00–1.93) 1.00 (0.51–1.95) 
  Men 2.68 (2.11–3.41) 1.15 (0.89–1.49) 1.01 (0.78–1.30) 2.86 (1.74–4.71) 1.21 (0.72–2.04) 0.87 (0.52–1.46) 
  Women 1.93 (1.48–2.52) 0.93 (0.70–1.24) 0.87 (0.66–1.16) 2.94 (1.95–4.42) 1.47 (0.95–2.27) 1.23 (0.80–1.91) 
 ≥70 Overall 0.83 (0.69–1.00) 0.78 (0.66–0.92) 0.73 (0.62–0.87) 1.09 (0.84–1.40) 0.84 (0.67–1.04) 0.76 (0.61–0.95) 
  Men 0.86 (0.65–1.14) 0.82 (0.64–1.05) 0.79 (0.62–1.01) 1.34 (0.93–1.94) 1.03 (0.75–1.43) 0.97 (0.70–1.34) 
  Women 0.81 (0.63–1.03) 0.75 (0.60–0.94) 0.70 (0.56–0.87) 0.92 (0.65–1.30) 0.71 (0.52–0.96) 0.64 (0.47–0.86) 
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   Unadjusted1 Age and sex 
adjusted2 
Fully adjusted3 Unadjusted1 Age and sex adjusted2 Fully adjusted3 
Mesenteric thrombosis <70 Overall 3.25 (2.42–4.37) 1.24 (0.89–1.73) 0.84 (0.61–1.16) 5.47 (3.33–8.99) 2.16 (1.24–3.77) 1.04 (0.60–1.80) 
  Men 2.87 (1.72–4.77) 0.98 (0.57–1.71) 0.72 (0.43–1.22) 4.34 (1.59–11.83) 1.42 (0.48–4.25) 0.75 (0.26–2.17) 
  Women 3.39 (2.36–4.87) 1.43 (0.94–2.17) 1.01 (0.67–1.52) 5.66 (3.21–9.99) 2.59 (1.36–4.94) 1.40 (0.73–2.69) 
 ≥70 Overall 0.66 (0.49–0.89) 0.60 (0.46–0.79) 0.53 (0.41–0.70) 0.95 (0.64–1.43) 0.74 (0.52–1.05) 0.62 (0.43–0.89) 
  Men 0.65 (0.39–1.09) 0.61 (0.38–0.98) 0.52 (0.32–0.83) 0.81 (0.44–1.49) 0.69 (0.40–1.18) 0.54 (0.31–0.94) 
  Women 0.66 (0.46–0.95) 0.60 (0.44–0.84) 0.55 (0.40–0.77) 1.00 (0.60–1.68) 0.76 (0.48–1.20) 0.67 (0.42–1.08) 
Lower limb fracture <70 Overall 1.71 (1.55–1.87) 1.01 (0.91–1.11) 0.85 (0.77–0.93) 2.26 (1.91–2.67) 1.35 (1.13–1.60) 0.98 (0.83–1.17) 
  Men 1.35 (1.15–1.58) 0.98 (0.83–1.16) 0.86 (0.73–1.02) 2.22 (1.67–2.93) 1.60 (1.20–2.14) 1.24 (0.93–1.66) 
  Women 1.91 (1.70–2.15) 1.03 (0.91–1.16) 0.88 (0.78–0.99) 2.21 (1.80–2.72) 1.25 (1.01–1.55) 0.95 (0.77–1.18) 
 ≥70 Overall 1.11 (1.02–1.21) 0.94 (0.88–1.01) 0.83 (0.78–0.89) 1.56 (1.39–1.76) 0.95 (0.87–1.04) 0.78 (0.71–0.85) 
  Men 1.06 (0.90–1.24) 0.94 (0.83–1.08) 0.84 (0.73–0.95) 1.50 (1.19–1.89) 0.97 (0.81–1.17) 0.81 (0.67–0.97) 
  Women 1.11 (1.01–1.22) 0.95 (0.88–1.03) 0.84 (0.77–0.91) 1.51 (1.32–1.73) 0.95 (0.85–1.06) 0.78 (0.70–0.87) 
Death <70 Overall 1.96 (1.87–2.06) 0.60 (0.57–0.63) 0.37 (0.35–0.39) 4.51 (4.20–4.85) 1.41 (1.30–1.53) 0.51 (0.47–0.56) 
  Men 2.35 (2.20–2.51) 0.63 (0.58–0.67) 0.44 (0.41–0.47) 6.47 (5.87–7.13) 1.57 (1.40–1.75) 0.75 (0.67–0.85) 
  Women 1.69 (1.56–1.82) 0.56 (0.52–0.61) 0.36 (0.33–0.39) 3.48 (3.13–3.89) 1.21 (1.07–1.37) 0.50 (0.44–0.57) 
 ≥70 Overall 0.35 (0.34–0.36) 0.34 (0.33–0.35) 0.28 (0.28–0.29) 0.49 (0.47–0.51) 0.38 (0.37–0.39) 0.27 (0.26–0.28) 
  Men 0.31 (0.30–0.32) 0.32 (0.31–0.33) 0.26 (0.25–0.27) 0.44 (0.42–0.47) 0.37 (0.35–0.38) 0.26 (0.24–0.27) 
  Women 0.39 (0.37–0.40) 0.36 (0.35–0.37) 0.30 (0.29–0.31) 0.54 (0.51–0.56) 0.39 (0.38–0.41) 0.29 (0.27–0.30) 
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Outcome Age Sex 1-28 days post-vaccination >28 days post vaccination s 
   Unadjusted1 Age and sex 
adjusted2 
Fully adjusted3 Unadjusted1 Age and sex adjusted2 Fully adjusted3 
         
(B) BNT162b2 vaccine 
All venous events 
<70 Overall 1.47 (1.35–1.61) 1.01 (0.93–1.11) 0.81 (0.74–0.88) 1.14 (1.01–1.29) 0.88 (0.77–1.00) 0.73 (0.64–0.83) 
 Men 1.98 (1.75–2.23) 1.15 (1.01–1.30) 0.92 (0.81–1.05) 1.56 (1.28–1.89) 1.02 (0.83–1.25) 0.83 (0.68–1.02) 
 Women 1.20 (1.06–1.37) 0.91 (0.80–1.03) 0.74 (0.65–0.84) 1.01 (0.86–1.20) 0.81 (0.69–0.96) 0.70 (0.59–0.83) 
≥70 Overall 0.65 (0.60–0.71) 0.56 (0.52–0.61) 0.57 (0.53–0.62) 0.68 (0.62–0.75) 0.50 (0.46–0.55) 0.50 (0.45–0.55) 
  Men 0.67 (0.59–0.76) 0.59 (0.52–0.66) 0.60 (0.53–0.67) 0.75 (0.65–0.87) 0.59 (0.51–0.68) 0.58 (0.50–0.67) 
  Women 0.64 (0.58–0.72) 0.54 (0.49–0.60) 0.56 (0.50–0.63) 0.63 (0.56–0.72) 0.45 (0.40–0.51) 0.45 (0.40–0.52) 
Intracranial venous thrombosis <70 Overall 0.76 (0.31–1.85) 0.72 (0.29–1.78) 0.59 (0.24–1.45) 0.65 (0.20–2.13) 0.59 (0.18–1.93) 0.51 (0.16–1.68) 
  Men 1.60 (0.50–5.16) 1.39 (0.43–4.49) 1.09 (0.33–3.61) 1.04 (0.14–7.77) 0.92 (0.12–7.05) 0.74 (0.10–5.62) 
  Women 0.39 (0.10–1.60) 0.44 (0.11–1.78) 0.37 (0.09–1.52) 0.48 (0.11–2.07) 0.51 (0.12–2.20) 0.45 (0.10–1.95) 
 ≥70 Overall 1.65 (0.64–4.29) 1.25 (0.48–3.26) 1.43 (0.55–3.75) 1.13 (0.13–9.75) 0.71 (0.08–6.56) 0.88 (0.10–7.52) 
  Men - - - - - - 
  Women 2.01 (0.69–5.88) 1.45 (0.49–4.26) 1.57 (0.54–4.54) 1.26 (0.13–11.94) 0.73 (0.07–7.29) 0.82 (0.09–7.61) 
Portal vein thrombosis <70 Overall 0.58 (0.15–2.30) 0.44 (0.11–1.72) 0.29 (0.07–1.17) 3.06 (1.29–7.24) 2.84 (1.19–6.74) 2.19 (0.89–5.37) 
  Men 1.28 (0.33–4.95) 0.81 (0.21–3.09) 0.51 (0.13–2.04) - - - 
  Women - - - 5.30 (1.98–14.22) 4.28 (1.55–11.78) 3.95 (1.39–11.20) 
 ≥70 Overall 0.49 (0.10–2.28) 0.43 (0.10–1.87) 0.42 (0.09–1.91) 0.67 (0.23–1.97) 0.54 (0.19–1.56) 0.48 (0.17–1.38) 
  Men 0.85 (0.17–4.38) 0.55 (0.11–2.66) 0.49 (0.10–2.46) 1.26 (0.36–4.41) 0.70 (0.23–2.17) 0.48 (0.17–1.38) 
  Women 0.22 (0.01–3.38) 0.24 (0.01–3.80) 0.26 (0.02–4.47) 0.37 (0.09–1.52) 0.44 (0.10–2.01) 0.46 (0.11–2.04) 
Pulmonary embolism <70 Overall 1.52 (1.36–1.71) 0.99 (0.87–1.11) 0.78 (0.69–0.88) 1.20 (1.02–1.43) 0.89 (0.75–1.06) 0.71 (0.60–0.85) 
  Men 1.93 (1.63–2.28) 1.05 (0.88–1.25) 0.85 (0.71–1.01) 1.56 (1.19–2.05) 0.97 (0.74–1.29) 0.77 (0.58–1.03) 
  Women 1.32 (1.13–1.56) 0.94 (0.79–1.10) 0.75 (0.64–0.89) 1.10 (0.88–1.37) 0.84 (0.67–1.05) 0.71 (0.57–0.89) 
 ≥70 Overall 0.61 (0.55–0.68) 0.53 (0.48–0.59) 0.54 (0.49–0.60) 0.61 (0.54–0.69) 0.45 (0.40–0.51) 0.45 (0.39–0.50) 
  Men 0.64 (0.55–0.75) 0.56 (0.48–0.65) 0.57 (0.49–0.66) 0.65 (0.54–0.77) 0.50 (0.42–0.59) 0.49 (0.41–0.59) 
  Women 0.59 (0.52–0.68) 0.51 (0.44–0.58) 0.52 (0.45–0.60) 0.58 (0.49–0.68) 0.42 (0.36–0.49) 0.42 (0.36–0.49) 
Deep vein thrombosis <70 Overall 1.38 (1.21–1.59) 1.03 (0.89–1.18) 0.82 (0.71–0.95) 1.05 (0.86–1.28) 0.85 (0.69–1.04) 0.73 (0.59–0.89) 
  Men 1.93 (1.60–2.33) 1.23 (1.01–1.49) 0.99 (0.81–1.20) 1.55 (1.15–2.10) 1.10 (0.81–1.48) 0.94 (0.69–1.28) 
  Women 1.08 (0.88–1.33) 0.87 (0.71–1.08) 0.72 (0.58–0.89) 0.88 (0.67–1.15) 0.74 (0.56–0.97) 0.65 (0.50–0.86) 
 ≥70 Overall 0.69 (0.60–0.79) 0.58 (0.51–0.67) 0.61 (0.53–0.70) 0.81 (0.69–0.96) 0.59 (0.50–0.70) 0.61 (0.52–0.73) 
  Men 0.66 (0.53–0.82) 0.59 (0.48–0.73) 0.61 (0.49–0.76) 0.95 (0.74–1.23) 0.78 (0.60–1.01) 0.80 (0.61–1.05) 
  Women 0.71 (0.59–0.85) 0.59 (0.49–0.70) 0.62 (0.52–0.74) 0.72 (0.58–0.90) 0.49 (0.40–0.61) 0.52 (0.41–0.64) 
Other <70 Overall 2.16 (1.47–3.19) 1.60 (1.07–2.37) 1.18 (0.79–1.77) 1.64 (0.93–2.90) 1.34 (0.75–2.40) 1.03 (0.57–1.87) 
  Men 3.25 (1.93–5.50) 2.03 (1.16–3.54) 1.46 (0.83–2.57) 2.14 (0.86–5.34) 1.51 (0.59–3.86) 1.03 (0.39–2.70) 
  Women 1.48 (0.82–2.65) 1.20 (0.67–2.16) 0.98 (0.54–1.77) 1.55 (0.75–3.21) 1.31 (0.63–2.74) 1.21 (0.57–2.55) 
 ≥70 Overall 1.13 (0.66–1.94) 0.97 (0.58–1.64) 1.01 (0.60–1.72) 0.86 (0.39–1.88) 0.66 (0.31–1.41) 0.67 (0.30–1.47) 
  Men 1.50 (0.77–2.95) 1.25 (0.65–2.42) 1.27 (0.64–2.49) 1.51 (0.50–4.51) 1.09 (0.36–3.34) 1.07 (0.33–3.44) 
  Women 0.79 (0.31–2.04) 0.72 (0.30–1.75) 0.75 (0.30–1.85) 0.42 (0.17–1.06) 0.36 (0.15–0.88) 0.36 (0.14–0.91) 
All arterial events <70 Overall 2.21 (2.12–2.31) 1.31 (1.25–1.37) 0.94 (0.90–0.99) 1.45 (1.35–1.55) 1.08 (1.01–1.16) 0.88 (0.82–0.95) 
  Men 3.06 (2.90–3.22) 1.44 (1.36–1.52) 0.99 (0.93–1.05) 2.17 (1.99–2.38) 1.19 (1.08–1.31) 0.91 (0.82–1.00) 
  Women 1.85 (1.71–1.99) 1.11 (1.02–1.20) 0.92 (0.84–0.99) 1.44 (1.30–1.60) 0.96 (0.86–1.07) 0.91 (0.81–1.02) 
 ≥70 Overall 0.90 (0.87–0.93) 0.69 (0.66–0.71) 0.72 (0.70–0.75) 1.15 (1.10–1.20) 0.69 (0.66–0.72) 0.71 (0.68–0.74) 
  Men 0.96 (0.91–1.00) 0.75 (0.71–0.78) 0.77 (0.73–0.81) 1.17 (1.11–1.25) 0.74 (0.70–0.79) 0.74 (0.70–0.79) 
  Women 0.84 (0.80–0.89) 0.63 (0.60–0.66) 0.68 (0.65–0.71) 1.13 (1.06–1.20) 0.64 (0.61–0.68) 0.68 (0.64–0.73) 
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   Unadjusted1 Age and sex 
adjusted2 
Fully adjusted3 Unadjusted1 Age and sex adjusted2 Fully adjusted3 
Myocardial infarction <70 Overall 2.24 (2.12–2.37) 1.39 (1.30–1.47) 0.94 (0.88–1.00) 1.42 (1.29–1.55) 1.14 (1.04–1.26) 0.88 (0.80–0.97) 
  Men 3.07 (2.87–3.28) 1.51 (1.40–1.62) 0.97 (0.90–1.05) 1.98 (1.76–2.23) 1.13 (1.00–1.28) 0.81 (0.71–0.93) 
  Women 1.94 (1.74–2.17) 1.15 (1.03–1.30) 0.94 (0.83–1.06) 1.78 (1.54–2.05) 1.18 (1.02–1.37) 1.11 (0.95–1.30) 
 ≥70 Overall 0.93 (0.88–0.98) 0.74 (0.71–0.78) 0.74 (0.70–0.78) 1.19 (1.12–1.27) 0.78 (0.73–0.83) 0.75 (0.70–0.80) 
  Men 0.99 (0.92–1.06) 0.81 (0.76–0.86) 0.79 (0.73–0.84) 1.20 (1.10–1.31) 0.82 (0.76–0.89) 0.76 (0.70–0.83) 
  Women 0.85 (0.78–0.92) 0.66 (0.61–0.72) 0.69 (0.63–0.74) 1.20 (1.08–1.33) 0.74 (0.67–0.81) 0.74 (0.67–0.82) 
Ischaemic stroke4 <70 Overall 2.18 (2.05–2.33) 1.23 (1.14–1.31) 0.90 (0.83–0.97) 1.46 (1.32–1.62) 1.00 (0.89–1.11) 0.80 (0.72–0.90) 
  Men 3.05 (2.80–3.32) 1.38 (1.26–1.51) 0.95 (0.86–1.05) 2.40 (2.08–2.77) 1.26 (1.09–1.46) 0.91 (0.78–1.07) 
  Women 1.76 (1.59–1.96) 1.05 (0.94–1.17) 0.85 (0.76–0.95) 1.18 (1.01–1.38) 0.77 (0.66–0.90) 0.73 (0.61–0.86) 
 ≥70 Overall 0.88 (0.84–0.93) 0.65 (0.63–0.68) 0.71 (0.68–0.75) 1.13 (1.06–1.19) 0.64 (0.60–0.67) 0.69 (0.66–0.73) 
  Men 0.94 (0.88–1.00) 0.71 (0.66–0.75) 0.77 (0.72–0.82) 1.17 (1.07–1.27) 0.69 (0.64–0.75) 0.75 (0.69–0.81) 
  Women 0.84 (0.78–0.89) 0.61 (0.58–0.65) 0.68 (0.63–0.72) 1.09 (1.01–1.19) 0.60 (0.56–0.65) 0.66 (0.61–0.71) 
Other arterial <70 Overall 1.72 (1.28–2.31) 0.95 (0.70–1.30) 0.69 (0.50–0.94) 1.63 (1.10–2.43) 1.13 (0.74–1.72) 0.85 (0.55–1.32) 
  Men 2.31 (1.58–3.37) 0.99 (0.66–1.49) 0.71 (0.47–1.07) 3.22 (2.02–5.13) 1.56 (0.95–2.58) 1.16 (0.69–1.96) 
  Women 1.46 (0.90–2.37) 0.88 (0.54–1.45) 0.69 (0.42–1.15) 0.93 (0.43–1.99) 0.65 (0.30–1.43) 0.59 (0.26–1.33) 
 ≥70 Overall 0.59 (0.46–0.76) 0.51 (0.40–0.65) 0.52 (0.41–0.67) 0.64 (0.47–0.85) 0.47 (0.35–0.62) 0.46 (0.34–0.62) 
  Men 0.49 (0.35–0.69) 0.46 (0.32–0.65) 0.47 (0.33–0.66) 0.52 (0.37–0.74) 0.46 (0.32–0.66) 0.44 (0.31–0.64) 
  Women 0.74 (0.51–1.08) 0.59 (0.41–0.84) 0.60 (0.42–0.85) 0.83 (0.50–1.37) 0.50 (0.31–0.79) 0.49 (0.30–0.78) 
Haematological events         
Any thrombocytopenia <70 Overall 2.10 (1.60–2.77) 1.48 (1.11–1.97) 1.00 (0.75–1.34) 2.03 (1.42–2.92) 1.54 (1.07–2.23) 0.97 (0.66–1.41) 
  Men 3.31 (2.23–4.91) 2.07 (1.35–3.16) 1.19 (0.78–1.83) 2.95 (1.61–5.42) 2.02 (1.08–3.79) 0.93 (0.49–1.78) 
  Women 1.50 (1.01–2.22) 1.17 (0.78–1.74) 0.97 (0.65–1.46) 1.58 (1.00–2.50) 1.32 (0.83–2.08) 1.14 (0.72–1.80) 
 ≥70 Overall 0.85 (0.64–1.13) 0.72 (0.54–0.95) 0.68 (0.51–0.90) 1.22 (0.87–1.71) 0.90 (0.64–1.25) 0.79 (0.56–1.12) 
  Men 0.87 (0.61–1.26) 0.73 (0.51–1.05) 0.68 (0.47–0.97) 1.55 (1.03–2.32) 1.12 (0.75–1.67) 0.95 (0.62–1.46) 
  Women 0.82 (0.53–1.29) 0.71 (0.46–1.09) 0.68 (0.44–1.07) 0.84 (0.48–1.48) 0.63 (0.36–1.09) 0.57 (0.32–1.02) 
Other events         
Haemorrhagic stroke5 <70 Overall 1.39 (1.13–1.71) 0.83 (0.67–1.03) 0.77 (0.62–0.96) 1.31 (1.00–1.73) 0.90 (0.68–1.19) 0.86 (0.65–1.15) 
  Men 1.65 (1.22–2.23) 0.86 (0.63–1.18) 0.77 (0.57–1.05) 1.43 (0.89–2.29) 0.86 (0.53–1.40) 0.77 (0.47–1.25) 
  Women 1.28 (0.95–1.72) 0.80 (0.59–1.08) 0.78 (0.58–1.05) 1.34 (0.95–1.88) 0.89 (0.62–1.26) 0.92 (0.65–1.31) 
 ≥70 Overall 0.80 (0.69–0.91) 0.59 (0.52–0.68) 0.65 (0.57–0.74) 1.28 (1.09–1.50) 0.72 (0.62–0.84) 0.80 (0.68–0.94) 
  Men 0.82 (0.67–1.01) 0.59 (0.48–0.71) 0.64 (0.52–0.78) 1.45 (1.14–1.83) 0.78 (0.62–0.98) 0.86 (0.68–1.09) 
  Women 0.78 (0.65–0.94) 0.60 (0.50–0.72) 0.66 (0.55–0.79) 1.16 (0.93–1.44) 0.68 (0.56–0.84) 0.76 (0.61–0.93) 
Mesenteric thrombosis <70 Overall 1.61 (1.10–2.36) 0.84 (0.56–1.26) 0.65 (0.43–0.97) 1.77 (1.11–2.84) 1.08 (0.66–1.75) 0.83 (0.50–1.37) 
  Men 2.91 (1.78–4.75) 1.29 (0.77–2.17) 0.97 (0.57–1.64) 2.21 (0.99–4.94) 1.15 (0.50–2.62) 0.82 (0.35–1.91) 
  Women 0.91 (0.49–1.67) 0.55 (0.29–1.03) 0.45 (0.23–0.86) 1.61 (0.90–2.88) 1.09 (0.60–1.98) 0.94 (0.50–1.75) 
 ≥70 Overall 0.72 (0.57–0.90) 0.54 (0.43–0.67) 0.54 (0.44–0.68) 1.06 (0.81–1.37) 0.61 (0.48–0.78) 0.59 (0.45–0.76) 
  Men 0.57 (0.37–0.86) 0.41 (0.27–0.61) 0.42 (0.28–0.62) 0.82 (0.53–1.29) 0.44 (0.29–0.66) 0.42 (0.27–0.65) 
  Women 0.80 (0.61–1.04) 0.61 (0.47–0.80) 0.62 (0.48–0.81) 1.18 (0.86–1.63) 0.72 (0.53–0.98) 0.70 (0.51–0.96) 
Lower limb fracture <70 Overall 1.44 (1.31–1.59) 1.03 (0.93–1.14) 0.93 (0.84–1.02) 1.24 (1.08–1.42) 0.95 (0.83–1.09) 0.89 (0.78–1.03) 
  Men 1.19 (0.99–1.42) 0.94 (0.78–1.12) 0.85 (0.71–1.02) 0.99 (0.74–1.31) 0.83 (0.62–1.11) 0.80 (0.60–1.07) 
  Women 1.49 (1.33–1.67) 1.08 (0.96–1.21) 0.98 (0.87–1.10) 1.27 (1.09–1.48) 1.00 (0.85–1.17) 0.94 (0.80–1.11) 
 ≥70 Overall 0.99 (0.93–1.05) 0.65 (0.62–0.69) 0.69 (0.66–0.73) 1.48 (1.38–1.59) 0.67 (0.63–0.72) 0.71 (0.66–0.76) 
  Men 0.95 (0.85–1.06) 0.58 (0.52–0.64) 0.63 (0.57–0.70) 1.60 (1.40–1.83) 0.65 (0.57–0.73) 0.69 (0.61–0.79) 
  Women 1.00 (0.93–1.07) 0.68 (0.64–0.73) 0.72 (0.67–0.77) 1.42 (1.30–1.55) 0.68 (0.63–0.73) 0.71 (0.65–0.77) 
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Outcome Age Sex 1-28 days post-vaccination >28 days post vaccination s 
   Unadjusted1 Age and sex 
adjusted2 
Fully adjusted3 Unadjusted1 Age and sex adjusted2 Fully adjusted3 
Death <70 Overall 0.74 (0.69–0.79) 0.35 (0.32–0.37) 0.24 (0.22–0.26) 0.91 (0.84–1.00) 0.52 (0.48–0.57) 0.33 (0.30–0.37) 
  Men 1.06 (0.97–1.17) 0.39 (0.36–0.43) 0.28 (0.25–0.31) 1.62 (1.44–1.82) 0.69 (0.61–0.79) 0.44 (0.39–0.51) 
  Women 0.56 (0.50–0.63) 0.29 (0.26–0.33) 0.22 (0.19–0.25) 0.66 (0.58–0.75) 0.38 (0.34–0.44) 0.28 (0.25–0.33) 
 ≥70 Overall 0.22 (0.22–0.23) 0.16 (0.16–0.16) 0.19 (0.19–0.20) 0.30 (0.29–0.31) 0.16 (0.16–0.16) 0.19 (0.18–0.19) 
  Men 0.23 (0.22–0.24) 0.16 (0.15–0.16) 0.19 (0.18–0.20) 0.33 (0.32–0.34) 0.16 (0.15–0.17) 0.19 (0.18–0.19) 
  Women 0.21 (0.20–0.22) 0.16 (0.16–0.17) 0.20 (0.19–0.20) 0.27 (0.26–0.28) 0.16 (0.15–0.17) 0.19 (0.18–0.19) 
 
1Stratifed by region 
2Adjusted for age, age2, sex and stratified by region  
3Adjusted for age, age2, sex, ethnicity, deprivation, smoking and co-morbidities, and stratified by region 
4Ischaemic stroke: including ischaemic stroke, stroke of uncertain cause, and spinal stroke 
5Hemorrhagic stroke: including intracranial hemorrhage and subarachnoid hemorrhage 
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Supplementary table 2 (a) Fully adjusted hazard ratios (HRs) for the association of ChAdOx1-S and BNT162b2 with venous events 1-28 and >28 days after vaccination, within pre-
specified subgroups. P values for between subgroup differences were derived using Wald tests. OCP: oral contraceptive. HRT: hormone replacement therapy 
    ChAdOx1-S vaccine  BNT162b2 vaccine 
    
N 
(Events) 
Post vaccination ≤28 days Post vaccination >28 days 
N 
(Events) 
Post vaccination ≤28 days Post vaccination >28 days 
Subgroup   3001 HR (95% CI)1 P value HR (95% CI)1 P value 3133 HR (95% CI)1 P value HR (95% CI)1 P value 
Age groups 








30-39 63 1.33 (1.01–1.75) 0.85 (0.46–1.59) 60 0.90 (0.65–1.25) 0.71 (0.47–1.07) 
40-49 145 1.32 (1.09–1.61) 1.52 (1.09–2.13) 122 0.96 (0.77–1.21) 0.75 (0.56–1.01) 
50-59 270 0.93 (0.81–1.07) 1.00 (0.77–1.30) 237 0.78 (0.66–0.92) 0.69 (0.55–0.86) 
60-69 618 0.87 (0.79–0.96) 0.89 (0.73–1.07) 359 0.78 (0.69–0.89) 0.67 (0.55–0.83) 
70-79 1124 0.75 (0.69–0.82) 0.79 (0.71–0.88) 823 0.69 (0.62–0.77) 0.73 (0.65–0.82) 
80-89 546 0.79 (0.69–0.89) 0.73 (0.63–0.84) 1255 0.63 (0.56–0.70) 0.67 (0.61–0.74) 
>90 195 0.76 (0.62–0.94) 0.75 (0.59–0.95) 248 0.80 (0.65–0.99) 0.67 (0.55–0.81) 
Sex Male 1338 0.81 (0.75–0.87) 0.029 0.74 (0.66–0.82) 0.005 1423 0.70 (0.64–0.76) 0.150 0.66 (0.60–0.72) 0.024 
Female 1663 0.90 (0.84–0.97) 0.89 (0.81–0.98) 1710 0.75 (0.70–0.81) 0.74 (0.69–0.81) 
Ethnicity 








Asian or Asian British 38 0.51 (0.34–0.77) 0.66 (0.38–1.14) 56 0.69 (0.48–0.98) 0.57 (0.38–0.86) 
Black or Black British 53 0.91 (0.66–1.25) 0.62 (0.35–1.10) 42 0.62 (0.41–0.94) 0.61 (0.39–0.97) 
Mixed 10 0.47 (0.21–1.06) 0.76 (0.28–2.06) 12 0.74 (0.36–1.51) 0.43 (0.16–1.17) 
Other Ethnic Groups 17 0.73 (0.37–1.43) 1.63 (0.80–3.32) 23 1.30 (0.75–2.24) 0.94 (0.48–1.84) 
Unknown 21 1.11 (0.65–1.89) 1.14 (0.50–2.58) 15 0.74 (0.36–1.51) 0.68 (0.32–1.47) 
Missing 6 2.59 (1.05–6.42) 1.29 (0.18–9.32) 8 3.85 (1.67–8.87) 1.33 (0.33–5.43) 
Deprivation 








3-4 560 0.86 (0.77–0.96) 0.80 (0.68–0.93) 576 0.76 (0.67–0.85) 0.70 (0.62–0.80) 
5-6 625 0.90 (0.81–1.00) 0.82 (0.71–0.96) 606 0.70 (0.62–0.79) 0.67 (0.59–0.76) 
7-8 632 0.87 (0.78–0.97) 0.80 (0.69–0.93) 687 0.73 (0.65–0.82) 0.71 (0.63–0.80) 
9-10 (most) 609 0.91 (0.81–1.01) 0.92 (0.79–1.06) 770 0.81 (0.72–0.91) 0.88 (0.79–0.98) 
Prior thrombocytopenia No 3001 0.86 (0.82–0.91) 0.030 0.82 (0.76–0.89) 0.127 3132 0.73 (0.69–0.78) 0.014 0.71 (0.66–0.75) 0.372 
Yes 0 0.54 (0.35–0.82) 0.54 (0.31–0.93) <5 0.37 (0.21–0.63) 0.58 (0.38–0.89) 
Prior thrombophilia No 2986 0.86 (0.81–0.91) 0.093 0.82 (0.76–0.89) 0.130 3116 0.73 (0.69–0.77) 0.254 0.70 (0.66–0.75) 0.924 
Yes 15 0.50 (0.27–0.94) 0.38 (0.14–1.03) 17 0.48 (0.23–0.99) 0.68 (0.34–1.37) 
Prior venous event No 3001 0.95 (0.90–1.01) <0.0001 0.96 (0.88–1.05) <0.0001 3133 0.80 (0.76–0.86) <0.0001 0.78 (0.73–0.84) <0.0001 
Yes 0 0.54 (0.48–0.61) 0.42 (0.35–0.50) 0 0.44 (0.38–0.51) 0.44 (0.38–0.51) 
Prior COVID infection No 2839 0.88 (0.83–0.93) <0.001 0.85 (0.79–0.93) <0.0001 3012 0.74 (0.70–0.79) 0.001 0.72 (0.68–0.77) <0.001 
Yes 162 0.60 (0.49–0.74) 0.49 (0.37–0.64) 121 0.47 (0.36–0.61) 0.45 (0.34–0.58) 
OCP No 2996 1.15 (0.99–1.35) 0.382 1.03 (0.77–1.39) 0.786 3129 0.84 (0.70–1.00) 0.195 0.77 (0.61–0.97) 0.270 
Yes 5 0.69 (0.22–2.17) 1.26 (0.31–5.09) <5 0.33 (0.08–1.34) 0.34 (0.08–1.41) 
HRT No 2972 0.78 (0.73–0.83) 0.514 0.75 (0.69–0.82) 0.532 3112 0.69 (0.65–0.73) 0.554 0.66 (0.62–0.71) 0.949 
Yes 29 0.92 (0.56–1.50) 0.96 (0.45–2.05) 21 0.57 (0.30–1.08) 0.65 (0.34–1.23) 
Anticoagulant No 2759 0.98 (0.92–1.03) <0.0001 0.98 (0.90–1.07) <0.0001 2875 0.84 (0.79–0.89) <0.0001 0.83 (0.77–0.89) <0.0001 
Yes 242 0.34 (0.29–0.40) 0.28 (0.22–0.35) 258 0.25 (0.21–0.31) 0.27 (0.22–0.32) 
Antiplatelet No 2503 0.89 (0.84–0.95) <0.001 0.84 (0.77–0.92) 0.081 2513 0.75 (0.71–0.80) 0.011 0.72 (0.67–0.77) 0.220 
Yes 498 0.69 (0.61–0.78) 0.73 (0.62–0.85) 620 0.62 (0.55–0.71) 0.66 (0.58–0.75) 
Prior MI or stroke No 2603 0.88 (0.83–0.93) 0.004 0.87 (0.80–0.95) <0.0001 2680 0.74 (0.70–0.79) 0.021 0.72 (0.67–0.77) 0.086 
Yes 398 0.71 (0.62–0.82) 0.58 (0.48–0.69) 453 0.62 (0.53–0.72) 0.63 (0.55–0.73) 
Prior diabetes No 2363 0.88 (0.83–0.93) 0.053 0.85 (0.78–0.93) 0.034 2456 0.74 (0.70–0.79) 0.149 0.71 (0.66–0.76) 0.639 
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Supplementary table 2 (b) Fully adjusted hazard ratios (HRs) for the association of ChAdOx1-S and BNT162b2 with arterial events 1-28 and >28 days after vaccination, within pre-
specified subgroups. P values for between subgroup differences were derived using Wald tests. OCP: oral contraceptive. HRT: hormone replacement therapy 
    ChAdOx1-S vaccine  BNT162b2 vaccine 
    
N 
(Events) 
Post vaccination ≤28 days Post vaccination >28 days 
N 
(Events) 
Post vaccination ≤28 days Post vaccination >28 days 
Subgroup All arterial 12890 HR (95% CI)1 P value HR (95% CI)1 P value 16759 HR (95% CI)1 P value HR (95% CI)1 P value 
Age groups 








30-39 54 1.51 (1.11–2.06) 1.54 (0.87–2.72) 67 1.36 (1.00–1.86) 1.09 (0.74–1.61) 
40-49 277 1.37 (1.20–1.57) 1.29 (0.99–1.69) 284 1.17 (1.01–1.36) 0.86 (0.70–1.05) 
50-59 963 0.98 (0.91–1.05) 0.89 (0.76–1.04) 1062 1.06 (0.98–1.14) 0.81 (0.72–0.91) 
60-69 2442 0.85 (0.81–0.90) 0.90 (0.82–0.99) 1705 0.89 (0.84–0.95) 0.83 (0.76–0.92) 
70-79 5030 0.90 (0.86–0.94) 0.93 (0.88–0.99) 3993 0.85 (0.81–0.89) 0.91 (0.86–0.96) 
80-89 2826 0.86 (0.81–0.91) 0.88 (0.82–0.94) 7733 0.74 (0.71–0.78) 0.79 (0.76–0.82) 
>90 1286 0.85 (0.78–0.93) 0.86 (0.78–0.94) 1894 0.72 (0.66–0.79) 0.78 (0.73–0.84) 
Sex Male 7116 0.78 (0.75–0.80) <0.0001 0.75 (0.71–0.79) <0.0001 9292 0.77 (0.74–0.79) <0.0001 0.71 (0.68–0.73) <0.0001 
Female 5774 0.89 (0.86–0.93) 0.87 (0.83–0.92) 7467 0.85 (0.82–0.88) 0.89 (0.85–0.92) 
Ethnicity 








Asian or Asian British 647 0.84 (0.76–0.93) 0.74 (0.64–0.86) 728 0.75 (0.67–0.84) 0.63 (0.56–0.71) 
Black or Black British 217 0.90 (0.75–1.07) 0.89 (0.70–1.15) 190 0.77 (0.62–0.94) 0.79 (0.64–0.99) 
Mixed 72 1.19 (0.90–1.57) 0.56 (0.32–0.98) 85 1.10 (0.82–1.49) 0.81 (0.57–1.17) 
Other Ethnic Groups 113 0.93 (0.73–1.18) 0.90 (0.64–1.28) 121 0.89 (0.69–1.15) 0.76 (0.57–1.01) 
Unknown 80 0.88 (0.67–1.16) 0.75 (0.49–1.16) 103 0.87 (0.64–1.18) 1.09 (0.83–1.44) 
Missing 32 3.01 (1.98–4.57) 1.91 (0.89–4.08) 40 2.87 (1.81–4.56) 2.87 (1.80–4.58) 
Deprivation 
1-2 (least) 2498 0.76 (0.71–0.80) 
<0.001 




3-4 2514 0.81 (0.76–0.85) 0.76 (0.71–0.82)   2980 0.76 (0.72–0.81) 0.74 (0.69–0.78) 
5-6 2683 0.85 (0.81–0.90) 0.79 (0.74–0.85)   3489 0.78 (0.74–0.83) 0.79 (0.75–0.84) 
7-8 2616 0.83 (0.78–0.87) 0.86 (0.80–0.92)   3693 0.82 (0.78–0.87) 0.83 (0.79–0.88) 
9-10 (most) 2541 0.89 (0.85–0.95) 0.88 (0.82–0.95)   3772 0.90 (0.85–0.95) 0.85 (0.80–0.89) 
Prior thrombocytopenia No 12889 0.82 (0.80–0.85) 0.334 0.80 (0.77–0.84) 0.499 16758 0.80 (0.78–0.82) 0.920 0.78 (0.76–0.81) 0.136 
Yes <5 0.75 (0.61–0.91) 0.73 (0.57–0.95) <5 0.81 (0.66–1.00) 0.67 (0.54–0.82) 
Prior thrombophilia No 12864 0.82 (0.80–0.85) 0.059 0.80 (0.77–0.83) 0.620 16735 0.80 (0.78–0.82) 0.499 0.78 (0.76–0.81) 0.098 
Yes 26 0.48 (0.28–0.84) 0.66 (0.32–1.39) 24 0.66 (0.38–1.15) 0.43 (0.21–0.88) 
Prior venous event No 12874 0.83 (0.81–0.85) 0.029 0.80 (0.77–0.84) 0.504 16751 0.81 (0.78–0.83) 0.022 0.79 (0.76–0.81) 0.002 
Yes 16 0.73 (0.66–0.82) 0.77 (0.67–0.88) 8 0.70 (0.63–0.79) 0.66 (0.59–0.74) 
Prior COVID infection No 12227 0.84 (0.81–0.86) <0.0001 0.83 (0.79–0.86) <0.0001 16234 0.81 (0.79–0.84) <0.0001 0.80 (0.77–0.82) <0.0001 
Yes 663 0.63 (0.57–0.70) 0.51 (0.45–0.59) 525 0.57 (0.50–0.65) 0.51 (0.45–0.59) 
OCP No 12889 0.91 (0.79–1.05) 0.983 0.89 (0.67–1.18) <0.0001 16759 0.91 (0.79–1.06) <0.0001 0.94 (0.75–1.16) <0.0001 
Yes <5 0.89 (0.12–6.51) 0.00 (0.00–0.00) 0 0.00 (0.00–0.00) 0.00 (0.00–0.00) 
HRT No 12832 0.85 (0.82–0.87) 0.293 0.84 (0.80–0.88) 0.820 16671 0.81 (0.78–0.83) 0.061 0.79 (0.76–0.81) 0.070 
Yes 58 1.01 (0.73–1.40) 0.79 (0.45–1.37) 88 1.10 (0.79–1.51) 1.08 (0.77–1.52) 
Anticoagulant No 10726 0.84 (0.82–0.87) <0.001 0.82 (0.78–0.85) 0.015 13715 0.83 (0.81–0.86) <0.0001 0.80 (0.77–0.83) <0.001 
Yes 2164 0.74 (0.69–0.79) 0.74 (0.68–0.80) 3044 0.66 (0.62–0.70) 0.71 (0.67–0.76) 
Antiplatelet No 7636 0.99 (0.96–1.03) <0.0001 1.06 (1.01–1.11) <0.0001 9770 0.96 (0.93–0.99) <0.0001 1.05 (1.01–1.09) <0.0001 
Yes 5254 0.65 (0.63–0.68) 0.59 (0.55–0.62) 6989 0.65 (0.63–0.67) 0.55 (0.53–0.57) 
Prior MI or stroke No 6931 1.09 (1.05–1.13) <0.0001 1.18 (1.12–1.24) <0.0001 9428 1.08 (1.04–1.12) <0.0001 1.22 (1.17–1.26) <0.0001 
Yes 5959 0.64 (0.61–0.66) 0.60 (0.57–0.63) 7331 0.60 (0.57–0.62) 0.51 (0.49–0.53) 
Prior diabetes 








Yes 4148 0.77 (0.73–0.80) 0.73 (0.69–0.78) 5070 0.72 (0.69–0.76) 0.70 (0.67–0.74) 
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Supplementary table 3. Characteristics of patient who had an ICVT event before and after vaccination. 
Only percentage are presented, as disclosure control does not allow numbers <5 to be released 
  ICVT before vaccination % 
ICVT after 




N  <210 <40 <20 <0.0001 
Sex Male 40 33 21 0.24 Female 60 67 79 
Age 
18 - 29 19 17 0 
<0.0001 
30 - 49 42 22 26 
50 - 69 30 36 16 
70 - 79 6 11 21 
80+ 3 14 37 
Ethnicity 
Asian or Asian British 15 6 0 
0.38 
Black or Black British 5 3 0 
Mixed 2 0 0 
Other ethnic groups 1 0 0 
White 75 92 100 
Unknown or missing 1 0 0 
Deprivation2 
1 - 2 29 17 11 
0.19 
3 - 4 20 14 26 
5 - 6 25 25 21 
7 - 8 13 25 16 
9 - 10 13 19 26 
Smoking status 
Current 19 28 11 
0.5 Former 21 17 32 
Never 57 56 58 
Medical history 
Stroke 5 6 11 <0.0001 
MI 3 6 0 0.01 
DVT or PE 8 6 5 <0.0001 
Thrombophilia 1 0 0 0.05 
Coronavirus infection3 6 6 0 <0.0001 
Diabetes 10 17 37 <0.0001 
Depression 26 36 16 <0.0001 
Obesity 37 31 42 <0.0001 
Cancer 17 28 37 <0.0001 
COPD 2 11 16 0.78 
Liver disease <1 3 0 0.61 
CKD 5 11 32 0.25 
Major surgery4 18 8 11 <0.0001 
Dementia 2 3 0 0.03 
Medications 
Antiplatelet 5 6 16 0.01 
BP lowering 15 28 42 <0.0001 
Lipid lowering 12 22 26 <0.0001 
Anticoagulant 10 11 11 <0.0001 
Oral contraceptive 4 0 0 <0.0001 
HRT 1 0 0 0.05 
Number of 
diagnoses5 
0 71 50 58 0.04 1 - 5 29 50 42 
Number of 
medications 
0 31 11 2 
0.02 1 - 5 62 83 5 
6+ 7 6 2 
1 Approximation if Chi squared test included one or more zero counts; 2 Index of Multiple Deprivation deciles 
where 1 indicates least deprived and 10 indicates most deprived; 3 After 31/12/2019 and prior to 08/12/2020; 4 
In the last year; 5 The category ‘6+’ contained no individuals and so was excluded. 
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Supplementary figure 1: Cumulative incidence of vaccines of different types during follow up 
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Supplementary Figure 3 Hazard ratios for major (A) arterial and (B) venous thrombotic events, and (C) haematological events,other events and lower limb fractures recorded in any position in EHR
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Supplementary Figure 4: Hazard ratios for major (A) arterial and (B) venous thrombotic events, (C) haematological events, other events and fractures recorded in death record or in hospital record in first position 
followed by death <28 days
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